<PubmedArticle><MedlineCitation Status="MEDLINE" Owner="NLM" IndexingMethod="Automated"><PMID Version="1">39010093</PMID><DateCompleted><Year>2024</Year><Month>07</Month><Day>16</Day></DateCompleted><DateRevised><Year>2024</Year><Month>07</Month><Day>17</Day></DateRevised><Article PubModel="Electronic"><Journal><ISSN IssnType="Electronic">1423-0127</ISSN><JournalIssue CitedMedium="Internet"><Volume>31</Volume><Issue>1</Issue><PubDate><Year>2024</Year><Month>Jul</Month><Day>15</Day></PubDate></JournalIssue><Title>Journal of biomedical science</Title><ISOAbbreviation>J Biomed Sci</ISOAbbreviation></Journal><ArticleTitle>Enteroviruses: epidemic potential, challenges and opportunities with vaccines.</ArticleTitle><Pagination><StartPage>73</StartPage><MedlinePgn>73</MedlinePgn></Pagination><ELocationID EIdType="pii" ValidYN="Y">73</ELocationID><ELocationID EIdType="doi" ValidYN="Y">10.1186/s12929-024-01058-x</ELocationID><Abstract><AbstractText>Enteroviruses (EVs) are the most prevalent viruses in humans. EVs can cause a range of acute symptoms, from mild common colds to severe systemic infections such as meningitis, myocarditis, and flaccid paralysis. They can also lead to chronic diseases such as cardiomyopathy. Although more than 280 human EV serotypes exist, only four serotypes have licenced vaccines. No antiviral drugs are available to treat EV infections, and global surveillance of EVs has not been effectively coordinated. Therefore, poliovirus still circulates, and there have been alarming epidemics of non-polio enteroviruses. Thus, there is a pressing need for coordinated preparedness efforts against EVs.This review provides a perspective on recent enterovirus outbreaks and global poliovirus eradication efforts with continuous vaccine development initiatives. It also provides insights into the challenges and opportunities in EV vaccine development. Given that traditional whole-virus vaccine technologies are not suitable for many clinically relevant EVs and considering the ongoing risk of enterovirus outbreaks and the potential for new emerging pathogenic strains, the need for new effective and adaptable enterovirus vaccines is emphasized.This review also explores the difficulties in translating promising vaccine candidates for clinical use and summarizes information from published literature and clinical trial databases focusing on existing enterovirus vaccines, ongoing clinical trials, the obstacles faced in vaccine development as well as the emergence of new vaccine technologies. Overall, this review contributes to the understanding of enterovirus vaccines, their role in public health, and their significance as a tool for future preparedness.</AbstractText><CopyrightInformation>© 2024. The Author(s).</CopyrightInformation></Abstract><AuthorList CompleteYN="Y"><Author ValidYN="Y"><LastName>Jartti</LastName><ForeName>Minne</ForeName><Initials>M</Initials><Identifier Source="ORCID">0000-0002-4717-6068</Identifier><AffiliationInfo><Affiliation>Virology and Vaccine Immunology, Faculty of Medicine and Health Technology, Tampere University, Tampere, Finland.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Flodström-Tullberg</LastName><ForeName>Malin</ForeName><Initials>M</Initials><Identifier Source="ORCID">0000-0003-2685-2052</Identifier><AffiliationInfo><Affiliation>Department of Medicine Huddinge and Karolinska University Hospital, Karolinska Institutet, Stockholm, Sweden.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Hankaniemi</LastName><ForeName>Minna M</ForeName><Initials>MM</Initials><Identifier Source="ORCID">0000-0001-6463-1248</Identifier><AffiliationInfo><Affiliation>Virology and Vaccine Immunology, Faculty of Medicine and Health Technology, Tampere University, Tampere, Finland. minna.hankaniemi@tuni.fi.</Affiliation></AffiliationInfo></Author></AuthorList><Language>eng</Language><GrantList CompleteYN="Y"><Grant><GrantID>#355414</GrantID><Agency>Academy of Finland</Agency><Country /></Grant></GrantList><PublicationTypeList><PublicationType UI="D016428">Journal Article</PublicationType><PublicationType UI="D016454">Review</PublicationType></PublicationTypeList><ArticleDate DateType="Electronic"><Year>2024</Year><Month>07</Month><Day>15</Day></ArticleDate></Article><MedlineJournalInfo><Country>England</Country><MedlineTA>J Biomed Sci</MedlineTA><NlmUniqueID>9421567</NlmUniqueID><ISSNLinking>1021-7770</ISSNLinking></MedlineJournalInfo><ChemicalList><Chemical><RegistryNumber>0</RegistryNumber><NameOfSubstance UI="D014765">Viral Vaccines</NameOfSubstance></Chemical></ChemicalList><CitationSubset>IM</CitationSubset><MeshHeadingList><MeshHeading><DescriptorName UI="D006801" MajorTopicYN="N">Humans</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D004769" MajorTopicYN="Y">Enterovirus Infections</DescriptorName><QualifierName UI="Q000453" MajorTopicYN="N">epidemiology</QualifierName><QualifierName UI="Q000517" MajorTopicYN="N">prevention &amp; control</QualifierName><QualifierName UI="Q000821" MajorTopicYN="N">virology</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D004770" MajorTopicYN="Y">Enterovirus</DescriptorName><QualifierName UI="Q000276" MajorTopicYN="N">immunology</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D014765" MajorTopicYN="Y">Viral Vaccines</DescriptorName><QualifierName UI="Q000276" MajorTopicYN="N">immunology</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D000087506" MajorTopicYN="N">Vaccine Development</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D004196" MajorTopicYN="N">Disease Outbreaks</DescriptorName><QualifierName UI="Q000517" MajorTopicYN="N">prevention &amp; control</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D058872" MajorTopicYN="N">Epidemics</DescriptorName><QualifierName UI="Q000517" MajorTopicYN="N">prevention &amp; control</QualifierName></MeshHeading></MeshHeadingList><KeywordList Owner="NOTNLM"><Keyword MajorTopicYN="N">EV outbreaks</Keyword><Keyword MajorTopicYN="N">EV surveillance</Keyword><Keyword MajorTopicYN="N">Enterovirus (EV)</Keyword><Keyword MajorTopicYN="N">Vaccine development</Keyword></KeywordList><CoiStatement>MJ, MFT and MMH have no conflicts of interest.</CoiStatement></MedlineCitation><PubmedData><History><PubMedPubDate PubStatus="received"><Year>2024</Year><Month>3</Month><Day>14</Day></PubMedPubDate><PubMedPubDate PubStatus="accepted"><Year>2024</Year><Month>6</Month><Day>23</Day></PubMedPubDate><PubMedPubDate PubStatus="medline"><Year>2024</Year><Month>7</Month><Day>16</Day><Hour>11</Hour><Minute>43</Minute></PubMedPubDate><PubMedPubDate PubStatus="pubmed"><Year>2024</Year><Month>7</Month><Day>16</Day><Hour>0</Hour><Minute>41</Minute></PubMedPubDate><PubMedPubDate PubStatus="entrez"><Year>2024</Year><Month>7</Month><Day>15</Day><Hour>23</Hour><Minute>41</Minute></PubMedPubDate><PubMedPubDate PubStatus="pmc-release"><Year>2024</Year><Month>7</Month><Day>15</Day></PubMedPubDate></History><PublicationStatus>epublish</PublicationStatus><ArticleIdList><ArticleId IdType="pubmed">39010093</ArticleId><ArticleId IdType="pmc">PMC11247760</ArticleId><ArticleId IdType="doi">10.1186/s12929-024-01058-x</ArticleId><ArticleId IdType="pii">10.1186/s12929-024-01058-x</ArticleId></ArticleIdList><ReferenceList><Reference><Citation>Simmonds P, Gorbalenya AE, Harvala H, Hovi T, Knowles NJ, Lindberg AM, et al. Recommendations for the nomenclature of enteroviruses and rhinoviruses. Arch Virol. 2020;165:793–7. doi: 10.1007/s00705-019-04520-6.</Citation><ArticleIdList><ArticleId IdType="doi">10.1007/s00705-019-04520-6</ArticleId><ArticleId IdType="pmc">PMC7024059</ArticleId><ArticleId IdType="pubmed">31980941</ArticleId></ArticleIdList></Reference><Reference><Citation>International Committee on Taxonomy of Viruses: ICTV. Available at https://ictv.global/report/chapter/picornaviridae/picornaviridae/enterovirus.</Citation></Reference><Reference><Citation>Lulla V, Dinan AM, Hosmillo M, Chaudhry Y, Sherry L, Irigoyen N, et al. An upstream protein-coding region in enteroviruses modulates virus infection in gut epithelial cells. Nat Microbiol. 2019;4:280–92. doi: 10.1038/s41564-018-0297-1.</Citation><ArticleIdList><ArticleId IdType="doi">10.1038/s41564-018-0297-1</ArticleId><ArticleId IdType="pmc">PMC6443042</ArticleId><ArticleId IdType="pubmed">30478287</ArticleId></ArticleIdList></Reference><Reference><Citation>Guo H, Li Y, Liu G, Jiang Y, Shen S, Bi R, et al. A second open reading frame in human enterovirus determines viral replication in intestinal epithelial cells. Nat Commun. 2019;10:4066. doi: 10.1038/s41467-019-12040-9.</Citation><ArticleIdList><ArticleId IdType="doi">10.1038/s41467-019-12040-9</ArticleId><ArticleId IdType="pmc">PMC6731315</ArticleId><ArticleId IdType="pubmed">31492846</ArticleId></ArticleIdList></Reference><Reference><Citation>Laitinen OH, Svedin E, Kapell S, Nurminen A, Hytönen VP, Flodström-Tullberg M. Enteroviral proteases: structure, host interactions and pathogenicity. Rev Med Virol. 2016;26:251–67. doi: 10.1002/rmv.1883.</Citation><ArticleIdList><ArticleId IdType="doi">10.1002/rmv.1883</ArticleId><ArticleId IdType="pmc">PMC7169145</ArticleId><ArticleId IdType="pubmed">27145174</ArticleId></ArticleIdList></Reference><Reference><Citation>Carré A, Vecchio F, Flodström-Tullberg M, You S, Mallone R. Coxsackievirus and type 1 diabetes: diabetogenic mechanisms and implications for prevention. Endocr Rev. 2023;44:737–51. doi: 10.1210/endrev/bnad007.</Citation><ArticleIdList><ArticleId IdType="doi">10.1210/endrev/bnad007</ArticleId><ArticleId IdType="pubmed">36884282</ArticleId></ArticleIdList></Reference><Reference><Citation>Paloheimo O, Ihalainen TO, Tauriainen S, Välilehto O, Kirjavainen S, Niskanen EA, et al. Coxsackievirus B3-induced cellular protrusions: structural characteristics and functional competence. J Virol. 2011;85:6714–24. doi: 10.1128/JVI.00247-10.</Citation><ArticleIdList><ArticleId IdType="doi">10.1128/JVI.00247-10</ArticleId><ArticleId IdType="pmc">PMC3126532</ArticleId><ArticleId IdType="pubmed">21525342</ArticleId></ArticleIdList></Reference><Reference><Citation>Bubba L, Broberg EK, Jasir A, Simmonds P, Harvala H, Redlberger-Fritz M, et al. Circulation of non-polio enteroviruses in 24 EU and EEA countries between 2015 and 2017: a retrospective surveillance study. Lancet Infect Dis. 2020;20:350–61. doi: 10.1016/S1473-3099(19)30566-3.</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/S1473-3099(19)30566-3</ArticleId><ArticleId IdType="pubmed">31870905</ArticleId></ArticleIdList></Reference><Reference><Citation>Gundamraj V, Hasbun R. Viral meningitis and encephalitis: an update. Curr Opin Infect Dis. 2023;36:177–85. doi: 10.1097/QCO.0000000000000922.</Citation><ArticleIdList><ArticleId IdType="doi">10.1097/QCO.0000000000000922</ArticleId><ArticleId IdType="pubmed">37093042</ArticleId></ArticleIdList></Reference><Reference><Citation>Marjomäki V, Flodström-Tullberg M. Coxsackie B virus. Trends Microbiol. 2022;30:606–7. doi: 10.1016/j.tim.2022.01.016.</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.tim.2022.01.016</ArticleId><ArticleId IdType="pubmed">35183399</ArticleId></ArticleIdList></Reference><Reference><Citation>Tschöpe C, Ammirati E, Bozkurt B, Caforio ALP, Cooper LT, Felix SB, et al. Myocarditis and inflammatory cardiomyopathy: current evidence and future directions. Nat Rev Cardiol. 2021;18:169–93. doi: 10.1038/s41569-020-00435-x.</Citation><ArticleIdList><ArticleId IdType="doi">10.1038/s41569-020-00435-x</ArticleId><ArticleId IdType="pmc">PMC7548534</ArticleId><ArticleId IdType="pubmed">33046850</ArticleId></ArticleIdList></Reference><Reference><Citation>Junttila N, Lévêque N, Kabue JP, Cartet G, Mushiya F, Muyembe-Tamfum J-J, et al. New enteroviruses, EV-93 and EV-94, associated with acute flaccid paralysis in the Democratic Republic of the Congo. J Med Virol. 2007;79:393–400. doi: 10.1002/jmv.20825.</Citation><ArticleIdList><ArticleId IdType="doi">10.1002/jmv.20825</ArticleId><ArticleId IdType="pubmed">17311342</ArticleId></ArticleIdList></Reference><Reference><Citation>Zhang M, Zhang Y, Hong M, Xiao J, Han Z, Song Y, et al. Molecular typing and characterization of a novel genotype of EV-B93 isolated from Tibet China. PLoS One. 2020;15:e0237652. doi: 10.1371/journal.pone.0237652.</Citation><ArticleIdList><ArticleId IdType="doi">10.1371/journal.pone.0237652</ArticleId><ArticleId IdType="pmc">PMC7447049</ArticleId><ArticleId IdType="pubmed">32841272</ArticleId></ArticleIdList></Reference><Reference><Citation>Mao Q, Wang Y, Bian L, Xu M, Liang Z. EV-A71 vaccine licensure: a first step for multivalent enterovirus vaccine to control HFMD and other severe diseases. Emerg Microbes Infect. 2016;5:e75. doi: 10.1038/emi.2016.73.</Citation><ArticleIdList><ArticleId IdType="doi">10.1038/emi.2016.73</ArticleId><ArticleId IdType="pmc">PMC5141264</ArticleId><ArticleId IdType="pubmed">27436364</ArticleId></ArticleIdList></Reference><Reference><Citation>Liu X, Tao Z, Wang H, Lin X, Song L, Li Y, et al. Complete genome analysis of human enterovirus B73 isolated from an acute flaccid paralysis patient in Shandong China. Virus Genes. 2014;49:38–44. doi: 10.1007/s11262-014-1077-5.</Citation><ArticleIdList><ArticleId IdType="doi">10.1007/s11262-014-1077-5</ArticleId><ArticleId IdType="pubmed">24792513</ArticleId></ArticleIdList></Reference><Reference><Citation>Holm-Hansen CC, Midgley SE, Fischer TK. Global emergence of enterovirus D68: a systematic review. Lancet Infect Dis. 2016;16:e64–75. doi: 10.1016/S1473-3099(15)00543-5.</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/S1473-3099(15)00543-5</ArticleId><ArticleId IdType="pubmed">26929196</ArticleId></ArticleIdList></Reference><Reference><Citation>González-Sanz R, Casas-Alba D, Launes C, Muñoz-Almagro C, Ruiz-García MM, Alonso M, et al. Molecular epidemiology of an enterovirus A71 outbreak associated with severe neurological disease, Spain, 2016. Euro Surveill. 2019;24:1800089. doi: 10.2807/1560-7917.ES.2019.24.7.1800089.</Citation><ArticleIdList><ArticleId IdType="doi">10.2807/1560-7917.ES.2019.24.7.1800089</ArticleId><ArticleId IdType="pmc">PMC6381658</ArticleId><ArticleId IdType="pubmed">30782267</ArticleId></ArticleIdList></Reference><Reference><Citation>Messacar K, Spence-Davizon E, Osborne C, Press C, Schreiner TL, Martin J, et al. Clinical characteristics of enterovirus A71 neurological disease during an outbreak in children in Colorado, USA, in 2018: an observational cohort study. Lancet Infect Dis. 2020;20:230–9. doi: 10.1016/S1473-3099(19)30632-2.</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/S1473-3099(19)30632-2</ArticleId><ArticleId IdType="pmc">PMC11284833</ArticleId><ArticleId IdType="pubmed">31859216</ArticleId></ArticleIdList></Reference><Reference><Citation>Kapadia RK, Gill CM, Baca C, McMenamin C, Kannappan A, Niehaus WN, et al. Enterovirus A71 causing meningoencephalitis and acute flaccid myelitis in a patient receiving rituximab. J Neuroimmunol. 2021;358:577639. doi: 10.1016/j.jneuroim.2021.577639.</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.jneuroim.2021.577639</ArticleId><ArticleId IdType="pubmed">34214953</ArticleId></ArticleIdList></Reference><Reference><Citation>Esposito S, Chidini G, Cinnante C, Napolitano L, Giannini A, Terranova L, et al. Acute flaccid myelitis associated with enterovirus-D68 infection in an otherwise healthy child. Virol J. 2017;14:4. doi: 10.1186/s12985-016-0678-0.</Citation><ArticleIdList><ArticleId IdType="doi">10.1186/s12985-016-0678-0</ArticleId><ArticleId IdType="pmc">PMC5234096</ArticleId><ArticleId IdType="pubmed">28081720</ArticleId></ArticleIdList></Reference><Reference><Citation>Fischer TK, Simmonds P, Harvala H. The importance of enterovirus surveillance in a post-polio world. Lancet Infect Dis. 2022;22:e35–40. doi: 10.1016/S1473-3099(20)30852-5.</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/S1473-3099(20)30852-5</ArticleId><ArticleId IdType="pubmed">34265258</ArticleId></ArticleIdList></Reference><Reference><Citation>Joo CH, Ahn J, Seo I, Kim YK, Kim D, Hong H, et al. Characterization of nonpolio enteroviruses recovered from patients with aseptic meningitis in Korea. Intervirology. 2005;48:97–103. doi: 10.1159/000081735.</Citation><ArticleIdList><ArticleId IdType="doi">10.1159/000081735</ArticleId><ArticleId IdType="pubmed">15812181</ArticleId></ArticleIdList></Reference><Reference><Citation>Wong AH, Lau CS, Cheng PKC, Ng AYY, Lim WWL. Coxsackievirus B3-associated aseptic meningitis: an emerging infection in Hong Kong. J Med Virol. 2011;83:483–9. doi: 10.1002/jmv.21998.</Citation><ArticleIdList><ArticleId IdType="doi">10.1002/jmv.21998</ArticleId><ArticleId IdType="pubmed">21264869</ArticleId></ArticleIdList></Reference><Reference><Citation>Muehlenbachs A, Bhatnagar J, Zaki SR. Tissue tropism, pathology and pathogenesis of enterovirus infection. J Pathol. 2015;235:217–28. doi: 10.1002/path.4438.</Citation><ArticleIdList><ArticleId IdType="doi">10.1002/path.4438</ArticleId><ArticleId IdType="pubmed">25211036</ArticleId></ArticleIdList></Reference><Reference><Citation>Lee KY, Lee MS, Kim DB. Neurologic Manifestations of Enterovirus 71 Infection in Korea. J Korean Med Sci. 2016;31:561. doi: 10.3346/jkms.2016.31.4.561.</Citation><ArticleIdList><ArticleId IdType="doi">10.3346/jkms.2016.31.4.561</ArticleId><ArticleId IdType="pmc">PMC4810339</ArticleId><ArticleId IdType="pubmed">27051240</ArticleId></ArticleIdList></Reference><Reference><Citation>Berger JR, Chumley W, Pittman T, Given C, Nuovo G. Persistent Coxsackie B encephalitis: report of a case and review of the literature. J Neurovirol. 2006;12:511–6. doi: 10.1080/13550280601090546.</Citation><ArticleIdList><ArticleId IdType="doi">10.1080/13550280601090546</ArticleId><ArticleId IdType="pubmed">17162666</ArticleId></ArticleIdList></Reference><Reference><Citation>Verma NA, Zheng XT, Harris MU, Cadichon SB, Melin-Aldana H, Khetsuriani N, et al. Outbreak of life-threatening Coxsackievirus B1 myocarditis in neonates. Clin Infect Dis. 2009;49:759–63. doi: 10.1086/605089.</Citation><ArticleIdList><ArticleId IdType="doi">10.1086/605089</ArticleId><ArticleId IdType="pubmed">19622042</ArticleId></ArticleIdList></Reference><Reference><Citation>Kim K-S, Hufnagel G, Chapman NM, Tracy S. The group B coxsackieviruses and myocarditis. Rev Med Virol. 2001;11:355–68. doi: 10.1002/rmv.326.</Citation><ArticleIdList><ArticleId IdType="doi">10.1002/rmv.326</ArticleId><ArticleId IdType="pubmed">11746998</ArticleId></ArticleIdList></Reference><Reference><Citation>de Graaf H, Pelosi E, Cooper A, Pappachan J, Sykes K, MacIntosh I, et al. Severe enterovirus infections in hospitalized children in the South of England. Pediatr Infect Dis J. 2016;35:723–7. doi: 10.1097/INF.0000000000001093.</Citation><ArticleIdList><ArticleId IdType="doi">10.1097/INF.0000000000001093</ArticleId><ArticleId IdType="pmc">PMC4985250</ArticleId><ArticleId IdType="pubmed">26882165</ArticleId></ArticleIdList></Reference><Reference><Citation>Bissel SJ, Winkler CC, DelTondo J, Wang G, Williams K, Wiley CA. Coxsackievirus B4 myocarditis and meningoencephalitis in newborn twins. Neuropathol. 2014;34:429–37. doi: 10.1111/neup.12121.</Citation><ArticleIdList><ArticleId IdType="doi">10.1111/neup.12121</ArticleId><ArticleId IdType="pmc">PMC4188796</ArticleId><ArticleId IdType="pubmed">24702280</ArticleId></ArticleIdList></Reference><Reference><Citation>Huber S, Ramsingh AI. Coxsackievirus-induced pancreatitis. Viral Immunol. 2004;17:358–69. doi: 10.1089/vim.2004.17.358.</Citation><ArticleIdList><ArticleId IdType="doi">10.1089/vim.2004.17.358</ArticleId><ArticleId IdType="pubmed">15357902</ArticleId></ArticleIdList></Reference><Reference><Citation>Zhang Y-F, Deng H-L, Fu J, Zhang Y, Wei J-Q. Pancreatitis in hand-foot-and-mouth disease caused by enterovirus 71. World J Gastroenterol. 2016;22:2149–52. doi: 10.3748/wjg.v22.i6.2149.</Citation><ArticleIdList><ArticleId IdType="doi">10.3748/wjg.v22.i6.2149</ArticleId><ArticleId IdType="pmc">PMC4726688</ArticleId><ArticleId IdType="pubmed">26877620</ArticleId></ArticleIdList></Reference><Reference><Citation>Zhang T, Du J, Xue Y, Su H, Yang F, Jin Q. Epidemics and frequent recombination within species in outbreaks of human enterovirus B-associated hand, foot and mouth disease in Shandong China in 2010 and 2011. PloS One. 2013;8:e67157. doi: 10.1371/journal.pone.0067157.</Citation><ArticleIdList><ArticleId IdType="doi">10.1371/journal.pone.0067157</ArticleId><ArticleId IdType="pmc">PMC3686723</ArticleId><ArticleId IdType="pubmed">23840610</ArticleId></ArticleIdList></Reference><Reference><Citation>Puenpa J, Mauleekoonphairoj J, Linsuwanon P, Suwannakarn K, Chieochansin T, Korkong S, et al. Prevalence and characterization of enterovirus infections among pediatric patients with hand foot mouth disease, herpangina and influenza like illness in Thailand, 2012. PloS One. 2014;9:e98888. doi: 10.1371/journal.pone.0098888.</Citation><ArticleIdList><ArticleId IdType="doi">10.1371/journal.pone.0098888</ArticleId><ArticleId IdType="pmc">PMC4041783</ArticleId><ArticleId IdType="pubmed">24887237</ArticleId></ArticleIdList></Reference><Reference><Citation>Hu Y-Q, Xie G-C, Li D-D, Pang L-L, Xie J, Wang P, et al. Prevalence of Coxsackievirus A6 and enterovirus 71 in hand, foot and mouth disease in Nanjing, China in 2013. Pediatr Infect Dis J. 2015;34:951. doi: 10.1097/INF.0000000000000794.</Citation><ArticleIdList><ArticleId IdType="doi">10.1097/INF.0000000000000794</ArticleId><ArticleId IdType="pubmed">26090576</ArticleId></ArticleIdList></Reference><Reference><Citation>Aswathyraj S, Arunkumar G, Alidjinou EK, Hober D. Hand, foot and mouth disease (HFMD): emerging epidemiology and the need for a vaccine strategy. Med Microbiol Immunol. 2016;205:397–407. doi: 10.1007/s00430-016-0465-y.</Citation><ArticleIdList><ArticleId IdType="doi">10.1007/s00430-016-0465-y</ArticleId><ArticleId IdType="pubmed">27406374</ArticleId></ArticleIdList></Reference><Reference><Citation>Yao X, Bian L-L, Lu W-W, Li J-X, Mao Q-Y, Wang Y-P, et al. Epidemiological and etiological characteristics of herpangina and hand foot mouth diseases in Jiangsu, China, 2013–2014. Hum Vaccin Immunother. 2016;13:823–30. doi: 10.1080/21645515.2016.1236879.</Citation><ArticleIdList><ArticleId IdType="doi">10.1080/21645515.2016.1236879</ArticleId><ArticleId IdType="pmc">PMC5404359</ArticleId><ArticleId IdType="pubmed">27768527</ArticleId></ArticleIdList></Reference><Reference><Citation>de Graaf H, Pelosi E, Cooper A, Pappachan J, Sykes K, MacIntosh I, et al. Severe enterovirus infections in hospitalized children in the South of England: clinical phenotypes and causative genotypes. Pediatr Infect Dis J. 2016;35:723–7. doi: 10.1097/INF.0000000000001093.</Citation><ArticleIdList><ArticleId IdType="doi">10.1097/INF.0000000000001093</ArticleId><ArticleId IdType="pmc">PMC4985250</ArticleId><ArticleId IdType="pubmed">26882165</ArticleId></ArticleIdList></Reference><Reference><Citation>Orbach R, Mandel D, Lubetzky R, Ovental A, Haham A, Halutz O, et al. Pulmonary hemorrhage due to Coxsackievirus B infection—A call to raise suspicion of this important complication as an end-stage of enterovirus sepsis in preterm twin neonates. J Clin Virol. 2016;82:41–5. doi: 10.1016/j.jcv.2016.07.003.</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.jcv.2016.07.003</ArticleId><ArticleId IdType="pubmed">27434146</ArticleId></ArticleIdList></Reference><Reference><Citation>Laitinen OH, Honkanen H, Pakkanen O, Oikarinen S, Hankaniemi MM, Huhtala H, et al. Coxsackievirus B1 is associated with induction of beta-cell autoimmunity that portends type 1 diabetes. Diabetes. 2014;63:446–55. doi: 10.2337/db13-0619.</Citation><ArticleIdList><ArticleId IdType="doi">10.2337/db13-0619</ArticleId><ArticleId IdType="pubmed">23974921</ArticleId></ArticleIdList></Reference><Reference><Citation>Stone VM, Hankaniemi MM, Svedin E, Sioofy-Khojine A, Oikarinen S, Hyoty H, et al. A Coxsackievirus B vaccine protects against virus-induced diabetes in an experimental mouse model of type 1 diabetes. Diabetologia. 2018;61:476–81. doi: 10.1007/s00125-017-4492-z.</Citation><ArticleIdList><ArticleId IdType="doi">10.1007/s00125-017-4492-z</ArticleId><ArticleId IdType="pmc">PMC6448957</ArticleId><ArticleId IdType="pubmed">29151123</ArticleId></ArticleIdList></Reference><Reference><Citation>Jaïdane H, Sané F, Gharbi J, Aouni M, Romond MB, Hober D. Coxsackievirus B4 and type 1 diabetes pathogenesis: contribution of animal models. Diabetes Metab Res Revs. 2009;25:591–603. doi: 10.1002/dmrr.995.</Citation><ArticleIdList><ArticleId IdType="doi">10.1002/dmrr.995</ArticleId><ArticleId IdType="pubmed">19621354</ArticleId></ArticleIdList></Reference><Reference><Citation>Esposito S, Zampiero A, Ruggiero L, Madini B, Niesters H, Principi N. Enterovirus D68-associated community-acquired pneumonia in children living in Milan. Italy. J Clin Virol. 2015;68:94–6. doi: 10.1016/j.jcv.2015.05.017.</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.jcv.2015.05.017</ArticleId><ArticleId IdType="pubmed">26071345</ArticleId></ArticleIdList></Reference><Reference><Citation>Zhou J, Li Y, Yin Q, Vinturache A, Ding G. Coxsackievirus A6 pneumonia in a child. Lancet Infect Dis. 2023;23:e567. doi: 10.1016/S1473-3099(23)00576-5.</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/S1473-3099(23)00576-5</ArticleId><ArticleId IdType="pubmed">38000879</ArticleId></ArticleIdList></Reference><Reference><Citation>Li H, Lao Q. The pulmonary complications associated with EV71-infected hand–foot–mouth disease. Radiol Infect Dis. 2017;4:137–42. doi: 10.1016/j.jrid.2017.01.001.</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.jrid.2017.01.001</ArticleId></ArticleIdList></Reference><Reference><Citation>Chia J, Chia A, Wang D, El-Habbal R, Sinkowitz D. Chronic enterovirus D68 bronchiolitis causing severe respiratory insufficiency. Open J Respir Dis. 2016;06:47–51. doi: 10.4236/ojrd.2016.63007.</Citation><ArticleIdList><ArticleId IdType="doi">10.4236/ojrd.2016.63007</ArticleId></ArticleIdList></Reference><Reference><Citation>Holm-Hansen CC, Midgley SE, Fischer TK. Global emergence of enterovirus D68: a systematic review. Lancet Infect Dis. 2016;16:64. doi: 10.1016/S1473-3099(15)00543-5.</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/S1473-3099(15)00543-5</ArticleId><ArticleId IdType="pubmed">26929196</ArticleId></ArticleIdList></Reference><Reference><Citation>Liu Y, Xi Y, Ji L, Shen Q, Zhang W, Xue M. Antiviral Drugs (Synthetic Small Molecule Inhibitors and Nature Drugs) Against EV71 in Enteroviruses: Advances and Perspectives. CCMP. 2023;3:100099. doi: 10.1016/j.ccmp.2023.100099.</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.ccmp.2023.100099</ArticleId></ArticleIdList></Reference><Reference><Citation>Lalani S, Gew LT, Poh CL. Antiviral peptides against Enterovirus A71 causing hand, foot and mouth disease. Peptides. 2021;136:170443. doi: 10.1016/j.peptides.2020.170443.</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.peptides.2020.170443</ArticleId><ArticleId IdType="pmc">PMC7648656</ArticleId><ArticleId IdType="pubmed">33171280</ArticleId></ArticleIdList></Reference><Reference><Citation>Wei Y, Liu H, Hu D, He Q, Yao C, Li H, et al. Recent advances in enterovirus A71 infection and antiviral agents. Lab Investig. 2024;104:100298. doi: 10.1016/j.labinv.2023.100298.</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.labinv.2023.100298</ArticleId><ArticleId IdType="pubmed">38008182</ArticleId></ArticleIdList></Reference><Reference><Citation>Lin J-Y, Kung Y-A, Shih S-R. Antivirals and vaccines for Enterovirus A71. J Biomed Sci. 2019;26:65. doi: 10.1186/s12929-019-0560-7.</Citation><ArticleIdList><ArticleId IdType="doi">10.1186/s12929-019-0560-7</ArticleId><ArticleId IdType="pmc">PMC6720414</ArticleId><ArticleId IdType="pubmed">31481071</ArticleId></ArticleIdList></Reference><Reference><Citation>Wang S, Pang Z, Fan H, Tong Y. Advances in anti-EV-A71 drug development research. J Adv Res. 2024;56:137–56. doi: 10.1016/j.jare.2023.03.007.</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.jare.2023.03.007</ArticleId><ArticleId IdType="pmc">PMC10834817</ArticleId><ArticleId IdType="pubmed">37001813</ArticleId></ArticleIdList></Reference><Reference><Citation>Diarimalala RO, Hu M, Wei Y, Hu K. Recent advances of enterovirus 71 3Cpro targeting Inhibitors. Virol J. 2020;17:173. doi: 10.1186/s12985-020-01430-x.</Citation><ArticleIdList><ArticleId IdType="doi">10.1186/s12985-020-01430-x</ArticleId><ArticleId IdType="pmc">PMC7657364</ArticleId><ArticleId IdType="pubmed">33176821</ArticleId></ArticleIdList></Reference><Reference><Citation>Lalani S, Poh CL. Flavonoids as Antiviral Agents for Enterovirus A71 (EV-A71) Viruses. 2020;12:184. doi: 10.3390/v12020184.</Citation><ArticleIdList><ArticleId IdType="doi">10.3390/v12020184</ArticleId><ArticleId IdType="pmc">PMC7077323</ArticleId><ArticleId IdType="pubmed">32041232</ArticleId></ArticleIdList></Reference><Reference><Citation>Tammaro C, Guida M, Appetecchia F, Biava M, Consalvi S, Poce G. Direct-acting antivirals and host-targeting approaches against enterovirus B infections: recent advances. Pharmaceuticals. 2023;16:203. doi: 10.3390/ph16020203.</Citation><ArticleIdList><ArticleId IdType="doi">10.3390/ph16020203</ArticleId><ArticleId IdType="pmc">PMC9966857</ArticleId><ArticleId IdType="pubmed">37259352</ArticleId></ArticleIdList></Reference><Reference><Citation>Hu Y, Musharrafieh R, Zheng M, Wang J. Enterovirus D68 antivirals: past, present, and future. ACS Infect Dis. 2020;6:1572–86. doi: 10.1021/acsinfecdis.0c00120.</Citation><ArticleIdList><ArticleId IdType="doi">10.1021/acsinfecdis.0c00120</ArticleId><ArticleId IdType="pmc">PMC8055446</ArticleId><ArticleId IdType="pubmed">32352280</ArticleId></ArticleIdList></Reference><Reference><Citation>Sun J, Hu X-Y, Yu X-F. Current Understanding of Human Enterovirus D68. Viruses. 2019;11:490. doi: 10.3390/v11060490.</Citation><ArticleIdList><ArticleId IdType="doi">10.3390/v11060490</ArticleId><ArticleId IdType="pmc">PMC6631698</ArticleId><ArticleId IdType="pubmed">31146373</ArticleId></ArticleIdList></Reference><Reference><Citation>Anasir MI, Zarif F, Poh CL. Antivirals blocking entry of enteroviruses and therapeutic potential. J Biomed Sci. 2021;28:10. doi: 10.1186/s12929-021-00708-8.</Citation><ArticleIdList><ArticleId IdType="doi">10.1186/s12929-021-00708-8</ArticleId><ArticleId IdType="pmc">PMC7811253</ArticleId><ArticleId IdType="pubmed">33451326</ArticleId></ArticleIdList></Reference><Reference><Citation>Glanville N, Johnston SL. Challenges in developing a cross-serotype rhinovirus vaccine. Curr Opin Virol. 2015;11:83–8. doi: 10.1016/j.coviro.2015.03.004.</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.coviro.2015.03.004</ArticleId><ArticleId IdType="pubmed">25829255</ArticleId></ArticleIdList></Reference><Reference><Citation>McLean GR. Developing a vaccine for human rhinoviruses. J Vaccines Immun. 2014;2:16–20. doi: 10.14312/2053-1273.2014-3.</Citation><ArticleIdList><ArticleId IdType="doi">10.14312/2053-1273.2014-3</ArticleId><ArticleId IdType="pmc">PMC4291752</ArticleId><ArticleId IdType="pubmed">25593706</ArticleId></ArticleIdList></Reference><Reference><Citation>GPEI: Outbreak Countries, https://polioeradication.org/where-we-work/polio-outbreak-countries/. Accessed 31 May 2024.</Citation></Reference><Reference><Citation>Link-Gelles R, Lutterloh E, Schnabel Ruppert P, Backenson PB, St. George K, Rosenberg ES, et al. Public Health Response to a Case of Paralytic Poliomyelitis in an Unvaccinated Person and Detection of Poliovirus in Wastewater — New York, June–August 2022. MMWR Morb Mortal Wkly Rep. 2022;71:1065–8. doi: 10.15585/mmwr.mm7133e2.</Citation><ArticleIdList><ArticleId IdType="doi">10.15585/mmwr.mm7133e2</ArticleId><ArticleId IdType="pmc">PMC9400530</ArticleId><ArticleId IdType="pubmed">35980868</ArticleId></ArticleIdList></Reference><Reference><Citation>Kalkowska DA, Badizadegan K, Routh JA, Burns CC, Rosenberg ES, Brenner IR, et al. Modeling undetected poliovirus circulation following the 2022 outbreak in the United States. Expert Rev Vacc. 2024;23:186–95. doi: 10.1080/14760584.2023.2299401.</Citation><ArticleIdList><ArticleId IdType="doi">10.1080/14760584.2023.2299401</ArticleId><ArticleId IdType="pmc">PMC11284832</ArticleId><ArticleId IdType="pubmed">38164695</ArticleId></ArticleIdList></Reference><Reference><Citation>WHO: Poliomyelitis. https://www.who.int/news-room/fact-sheets/detail/poliomyelitis. Accessed 4 March 2024.</Citation></Reference><Reference><Citation>Messacar K, Schreiner TL, Maloney JA, Wallace A, Ludke J, Oberste MS, et al. A cluster of acute flaccid paralysis and cranial nerve dysfunction temporally associated with an outbreak of enterovirus D68 in children in Colorado, USA. Lancet. 2015;385:1662–71. doi: 10.1016/S0140-6736(14)62457-0.</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/S0140-6736(14)62457-0</ArticleId><ArticleId IdType="pubmed">25638662</ArticleId></ArticleIdList></Reference><Reference><Citation>Gilrane VL, Zhuge J, Huang W, Nolan SM, Dhand A, Yin C, et al. Biennial Upsurge and Molecular Epidemiology of Enterovirus D68 Infection in New York, USA, 2014 to 2018. J Clin Microbiol. 2020;58:e00284–20. doi: 10.1128/JCM.00284-20.</Citation><ArticleIdList><ArticleId IdType="doi">10.1128/JCM.00284-20</ArticleId><ArticleId IdType="pmc">PMC7448634</ArticleId><ArticleId IdType="pubmed">32493783</ArticleId></ArticleIdList></Reference><Reference><Citation>Christy A, Messacar K. Acute flaccid myelitis associated with enterovirus D68: a review. J Child Neurol. 2019;34:511–6. doi: 10.1177/0883073819838376.</Citation><ArticleIdList><ArticleId IdType="doi">10.1177/0883073819838376</ArticleId><ArticleId IdType="pubmed">31014167</ArticleId></ArticleIdList></Reference><Reference><Citation>Martin JA, Messacar K, Yang ML, Maloney JA, Lindwall J, Carry T, et al. Outcomes of Colorado children with acute flaccid myelitis at 1 year. Neurology. 2017;89:129–37. doi: 10.1212/WNL.0000000000004081.</Citation><ArticleIdList><ArticleId IdType="doi">10.1212/WNL.0000000000004081</ArticleId><ArticleId IdType="pmc">PMC5501931</ArticleId><ArticleId IdType="pubmed">28615421</ArticleId></ArticleIdList></Reference><Reference><Citation>Messacar K, Robinson CC, Pretty K, Yuan J, Dominguez SR. Surveillance for enterovirus D68 in Colorado children reveals continued circulation. J Clin Virol. 2017;92:39–41. doi: 10.1016/j.jcv.2017.05.009.</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.jcv.2017.05.009</ArticleId><ArticleId IdType="pmc">PMC5625344</ArticleId><ArticleId IdType="pubmed">28521212</ArticleId></ArticleIdList></Reference><Reference><Citation>Fall A, Han L, Abdullah O, Norton JM, Eldesouki RE, Forman M, et al. An increase in enterovirus D68 circulation and viral evolution during a period of increased influenza like illness, The Johns Hopkins Health System, USA, 2022. J Clin Virol. 2023;160:105379. doi: 10.1016/j.jcv.2023.105379.</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.jcv.2023.105379</ArticleId><ArticleId IdType="pubmed">36652754</ArticleId></ArticleIdList></Reference><Reference><Citation>Peltola V, Österback R, Waris M, Ivaska L, Tähtinen PA, Laine M, et al. Enterovirus D68 Outbreak in Children, Finland, August–September 2022. Emerg Infect Dis. 2023;29:1258–61. doi: 10.3201/eid2906.221795.</Citation><ArticleIdList><ArticleId IdType="doi">10.3201/eid2906.221795</ArticleId><ArticleId IdType="pmc">PMC10202852</ArticleId><ArticleId IdType="pubmed">37209691</ArticleId></ArticleIdList></Reference><Reference><Citation>Uprety P, Curtis D, Elkan M, Fink J, Rajagopalan R, Zhao C, et al. Association of enterovirus D68 with acute flaccid myelitis, Philadelphia, Pennsylvania, USA, 2009–2018. Emerg Infect Dis. 2019;25:1676. doi: 10.3201/eid2509.190468.</Citation><ArticleIdList><ArticleId IdType="doi">10.3201/eid2509.190468</ArticleId><ArticleId IdType="pmc">PMC6711208</ArticleId><ArticleId IdType="pubmed">31407660</ArticleId></ArticleIdList></Reference><Reference><Citation>Murphy OC, Messacar K, Benson L, Bove R, Carpenter JL, Crawford T, et al. Acute flaccid myelitis: cause, diagnosis, and management. Lancet. 2021;397:334–46. doi: 10.1016/S0140-6736(20)32723-9.</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/S0140-6736(20)32723-9</ArticleId><ArticleId IdType="pmc">PMC7909727</ArticleId><ArticleId IdType="pubmed">33357469</ArticleId></ArticleIdList></Reference><Reference><Citation>Cao RG, Mejias A, Leber AL, Wang H. Clinical and molecular characteristics of the 2022 Enterovirus-D68 outbreak among hospitalized children, Ohio, USA. J Clin Vir. 2023;169:105618. doi: 10.1016/j.jcv.2023.105618.</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.jcv.2023.105618</ArticleId><ArticleId IdType="pubmed">37977074</ArticleId></ArticleIdList></Reference><Reference><Citation>Kamau E, Harvala H, Blomqvist S, Nguyen D, Horby P, Pebody R, et al. Increase in enterovirus D68 infections in young children, United Kingdom, 2006–2016. Emerg Infect Dis. 2019;25:1200–3. doi: 10.3201/eid2506.181759.</Citation><ArticleIdList><ArticleId IdType="doi">10.3201/eid2506.181759</ArticleId><ArticleId IdType="pmc">PMC6537723</ArticleId><ArticleId IdType="pubmed">30855226</ArticleId></ArticleIdList></Reference><Reference><Citation>Baggen J, Thibaut HJ, Staring J, Jae LT, Liu Y, Guo H, et al. Enterovirus D68 receptor requirements unveiled by haploid genetics. PNAS. 2016;113:1399–404. doi: 10.1073/pnas.1524498113.</Citation><ArticleIdList><ArticleId IdType="doi">10.1073/pnas.1524498113</ArticleId><ArticleId IdType="pmc">PMC4747778</ArticleId><ArticleId IdType="pubmed">26787879</ArticleId></ArticleIdList></Reference><Reference><Citation>Hixon AM, Yu G, Leser JS, Yagi S, Clarke P, Chiu CY, et al. A mouse model of paralytic myelitis caused by enterovirus D68. PLoS Pathog. 2017;13:e1006199. doi: 10.1371/journal.ppat.1006199.</Citation><ArticleIdList><ArticleId IdType="doi">10.1371/journal.ppat.1006199</ArticleId><ArticleId IdType="pmc">PMC5322875</ArticleId><ArticleId IdType="pubmed">28231269</ArticleId></ArticleIdList></Reference><Reference><Citation>Pons-Salort M, Grassly NC. Serotype-specific immunity explains the incidence of diseases caused by human enteroviruses. Science. 2018;361:800–3. doi: 10.1126/science.aat6777.</Citation><ArticleIdList><ArticleId IdType="doi">10.1126/science.aat6777</ArticleId><ArticleId IdType="pmc">PMC6559928</ArticleId><ArticleId IdType="pubmed">30139872</ArticleId></ArticleIdList></Reference><Reference><Citation>Pons-Salort M, Lambert B, Kamau E, Pebody R, Harvala H, Simmonds P, et al. Changes in transmission of Enterovirus D68 (EV-D68) in England inferred from seroprevalence data. Elife. 2023;12:e76609. doi: 10.7554/eLife.76609.</Citation><ArticleIdList><ArticleId IdType="doi">10.7554/eLife.76609</ArticleId><ArticleId IdType="pmc">PMC10259368</ArticleId><ArticleId IdType="pubmed">37294299</ArticleId></ArticleIdList></Reference><Reference><Citation>Tao L. Notes from the Field: Cluster of Parechovirus Central Nervous System Infections in Young Infants — Tennessee, 2022. MMWR Morb Mortal Wkly Rep. 2022;71. 10.15585/mmwr.mm7130a5.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC9345175</ArticleId><ArticleId IdType="pubmed">35900934</ArticleId></ArticleIdList></Reference><Reference><Citation>Singanayagam A, Moore C, Froude S, Celma C, Stowe J, Hani E, et al. Increased reports of severe myocarditis associated with enterovirus infection in neonates, United Kingdom, 27 June 2022 to 26 April 2023. Euro Surveill. 2023;28:2300313. doi: 10.2807/1560-7917.ES.2023.28.39.2300313.</Citation><ArticleIdList><ArticleId IdType="doi">10.2807/1560-7917.ES.2023.28.39.2300313</ArticleId><ArticleId IdType="pmc">PMC10540513</ArticleId><ArticleId IdType="pubmed">37768558</ArticleId></ArticleIdList></Reference><Reference><Citation>Enterovirus-Echovirus 11 Infection - the European Region. https://www.who.int/emergencies/disease-outbreak-news/item/2023-DON474. Accessed 15 Nov 2023.</Citation></Reference><Reference><Citation>Grapin M, Mirand A, Pinquier D, Basset A, Bendavid M, Bisseux M, et al. Severe and fatal neonatal infections linked to a new variant of echovirus 11, France, July 2022 to April 2023. Euro Surveill. 2023;28:2300253. doi: 10.2807/1560-7917.ES.2023.28.22.2300253.</Citation><ArticleIdList><ArticleId IdType="doi">10.2807/1560-7917.ES.2023.28.22.2300253</ArticleId><ArticleId IdType="pmc">PMC10236930</ArticleId><ArticleId IdType="pubmed">37261730</ArticleId></ArticleIdList></Reference><Reference><Citation>Qurbani K, Hussein S, Ahmed SK. Recent meningitis outbreak in Iraq: a looming threat to public health. Ther Adv Infect Dis. 2023;10:20499361231216586. doi: 10.1177/20499361231216586.</Citation><ArticleIdList><ArticleId IdType="doi">10.1177/20499361231216586</ArticleId><ArticleId IdType="pmc">PMC10714874</ArticleId><ArticleId IdType="pubmed">38090135</ArticleId></ArticleIdList></Reference><Reference><Citation>Fourgeaud J, Mirand A, Demortier J, Kamus L, Collet L, Olivier S, et al. Enterovirus meningitis in Mayotte French Comoros Island, March-June 2019. J Clin Vir. 2022;150–151:105154. doi: 10.1016/j.jcv.2022.105154.</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.jcv.2022.105154</ArticleId><ArticleId IdType="pubmed">35398601</ArticleId></ArticleIdList></Reference><Reference><Citation>Nkosi N, Preiser W, Van Zyl G, Claassen M, Cronje N, Maritz J, et al. Molecular characterisation and epidemiology of enterovirus-associated aseptic meningitis in the Western and Eastern Cape Provinces, South Africa 2018–2019. J Clin Vir. 2021;139:104845. doi: 10.1016/j.jcv.2021.104845.</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.jcv.2021.104845</ArticleId><ArticleId IdType="pubmed">33962182</ArticleId></ArticleIdList></Reference><Reference><Citation>Hasbun R, Wootton SH, Rosenthal N, Balada-Llasat JM, Chung J, Duff S, et al. Epidemiology of Meningitis and Encephalitis in Infants and Children in the United States, 2011–2014. Pediatr Infect Dis. 2019;38:37. doi: 10.1097/INF.0000000000002081.</Citation><ArticleIdList><ArticleId IdType="doi">10.1097/INF.0000000000002081</ArticleId><ArticleId IdType="pubmed">30531527</ArticleId></ArticleIdList></Reference><Reference><Citation>Broberg EK, Simone B, Jansa J. Upsurge in echovirus 30 detections in five EU/EEA countries, April to September, 2018. Euro Surveill. 2018;23:1800537. doi: 10.2807/1560-7917.ES.2018.23.44.1800537.</Citation><ArticleIdList><ArticleId IdType="doi">10.2807/1560-7917.ES.2018.23.44.1800537</ArticleId><ArticleId IdType="pmc">PMC6337069</ArticleId><ArticleId IdType="pubmed">30401013</ArticleId></ArticleIdList></Reference><Reference><Citation>Kriger O, Abramovich A, Fratty IS, Leshem E, Amit S, Stein M, et al. An Outbreak of Coxsackievirus B Type 2 Acute Meningoencephalitis in Children, Israel, July–September 2022. Pediatr Infect Dis. 2023;42:e177. doi: 10.1097/INF.0000000000003876.</Citation><ArticleIdList><ArticleId IdType="doi">10.1097/INF.0000000000003876</ArticleId><ArticleId IdType="pubmed">36795579</ArticleId></ArticleIdList></Reference><Reference><Citation>Tian X, Han Z, He Y, Sun Q, Wang W, Xu W, et al. Temporal phylogeny and molecular characterization of echovirus 30 associated with aseptic meningitis outbreaks in China. Virol J. 2021;18:118. doi: 10.1186/s12985-021-01590-4.</Citation><ArticleIdList><ArticleId IdType="doi">10.1186/s12985-021-01590-4</ArticleId><ArticleId IdType="pmc">PMC8182919</ArticleId><ArticleId IdType="pubmed">34092258</ArticleId></ArticleIdList></Reference><Reference><Citation>Gonzalez G, Carr MJ, Kobayashi M, Hanaoka N, Fujimoto T. Enterovirus-associated hand-foot and mouth disease and neurological complications in Japan and the rest of the world. Int J Mol Sci. 2019;20:5201. doi: 10.3390/ijms20205201.</Citation><ArticleIdList><ArticleId IdType="doi">10.3390/ijms20205201</ArticleId><ArticleId IdType="pmc">PMC6834195</ArticleId><ArticleId IdType="pubmed">31635198</ArticleId></ArticleIdList></Reference><Reference><Citation>Tan X, Huang X, Zhu S, Chen H, Yu Q, Wang H, et al. The persistent circulation of enterovirus 71 in People’s Republic of China: causing emerging nationwide epidemics since 2008. PLoS One. 2011;6:e25662. doi: 10.1371/journal.pone.0025662.</Citation><ArticleIdList><ArticleId IdType="doi">10.1371/journal.pone.0025662</ArticleId><ArticleId IdType="pmc">PMC3181342</ArticleId><ArticleId IdType="pubmed">21980521</ArticleId></ArticleIdList></Reference><Reference><Citation>Baek K, Yeo S, Lee B, Park K, Song J, Yu J, et al. Epidemics of enterovirus infection in Chungnam Korea, 2008 and 2009. Virol J. 2011;8:297. doi: 10.1186/1743-422X-8-297.</Citation><ArticleIdList><ArticleId IdType="doi">10.1186/1743-422X-8-297</ArticleId><ArticleId IdType="pmc">PMC3130694</ArticleId><ArticleId IdType="pubmed">21668960</ArticleId></ArticleIdList></Reference><Reference><Citation>Liu D-P, Wang T-A, Huang W-T, Chang L-Y, Wang E-T, Cheng S-H, et al. Disease burden of enterovirus infection in Taiwan: Implications for vaccination policy. Vaccine. 2016;34:974–80. doi: 10.1016/j.vaccine.2015.12.026.</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.vaccine.2015.12.026</ArticleId><ArticleId IdType="pubmed">26768128</ArticleId></ArticleIdList></Reference><Reference><Citation>Kang HJ, Yoon Y, Lee Y-P, Kim H-J, Lee D-Y, Lee J-W, et al. A Different Epidemiology of Enterovirus A and Enterovirus B Co-circulating in Korea, 2012–2019. JPIDS. 2021;10:398–407. doi: 10.1093/jpids/piaa111.</Citation><ArticleIdList><ArticleId IdType="doi">10.1093/jpids/piaa111</ArticleId><ArticleId IdType="pubmed">33150450</ArticleId></ArticleIdList></Reference><Reference><Citation>Chavan NA, Lavania M, Shinde P, Sahay R, Joshi M, Yadav PD, et al. The 2022 outbreak and the pathobiology of the coxsackie virus [hand foot and mouth disease] in India. Infect Genet Evol. 2023;111:105432. doi: 10.1016/j.meegid.2023.105432.</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.meegid.2023.105432</ArticleId><ArticleId IdType="pubmed">37030587</ArticleId></ArticleIdList></Reference><Reference><Citation>Puenpa J, Wanlapakorn N, Vongpunsawad S, Poovorawan Y. The history of enterovirus A71 outbreaks and molecular epidemiology in the Asia-Pacific Region. J Biomed Sci. 2019;26:75. doi: 10.1186/s12929-019-0573-2.</Citation><ArticleIdList><ArticleId IdType="doi">10.1186/s12929-019-0573-2</ArticleId><ArticleId IdType="pmc">PMC6798416</ArticleId><ArticleId IdType="pubmed">31627753</ArticleId></ArticleIdList></Reference><Reference><Citation>Chan LG, Parashar UD, Lye MS, Ong FGL, Zaki SR, Alexander JP, et al. Deaths of children during an outbreak of hand, foot, and mouth disease in Sarawak, Malaysia: clinical and pathological characteristics of the disease. Clin Infect Dis. 2000;31:678–83. doi: 10.1086/314032.</Citation><ArticleIdList><ArticleId IdType="doi">10.1086/314032</ArticleId><ArticleId IdType="pubmed">11017815</ArticleId></ArticleIdList></Reference><Reference><Citation>Donato C, Hoi LT, Hoa NT, Hoa TM, Van Duyet L, Dieu Ngan TT, et al. Genetic characterization of Enterovirus 71 strains circulating in Vietnam in 2012. Virology. 2016;495:1–9. doi: 10.1016/j.virol.2016.04.026.</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.virol.2016.04.026</ArticleId><ArticleId IdType="pubmed">27148893</ArticleId></ArticleIdList></Reference><Reference><Citation>Welch J, Maclaran K, Jordan T, Simmonds P. Frequency, viral loads, and serotype identification of enterovirus infections in Scottish blood donors. Transfusion. 2003;43:1060–6. doi: 10.1046/j.1537-2995.2003.00463.x.</Citation><ArticleIdList><ArticleId IdType="doi">10.1046/j.1537-2995.2003.00463.x</ArticleId><ArticleId IdType="pubmed">12869111</ArticleId></ArticleIdList></Reference><Reference><Citation>Huemer HP, Ortner B, Huang C-W, Schmid D, Mutz I, Wewalka G, et al. Isolating Asian enterovirus 71 subgenogroup C4 in two Austrian clinical samples from 2004. Euro Surveill. 2008;13:18922. doi: 10.2807/ese.13.28.18922-en.</Citation><ArticleIdList><ArticleId IdType="doi">10.2807/ese.13.28.18922-en</ArticleId><ArticleId IdType="pubmed">18761929</ArticleId></ArticleIdList></Reference><Reference><Citation>van der Sanden S, Koopmans M, Uslu G, van der Avoort H. Epidemiology of Enterovirus 71 in The Netherlands, 1963 to 2008. J Clin Microbiol. 2009;47:2826–33. doi: 10.1128/JCM.00507-09.</Citation><ArticleIdList><ArticleId IdType="doi">10.1128/JCM.00507-09</ArticleId><ArticleId IdType="pmc">PMC2738086</ArticleId><ArticleId IdType="pubmed">19625480</ArticleId></ArticleIdList></Reference><Reference><Citation>Badran SA, Midgley S, Andersen P, Böttiger B. Clinical and virological features of enterovirus 71 infections in Denmark, 2005 to 2008. Scand J Infect Dis. 2011;43:642–8. doi: 10.3109/00365548.2011.577094.</Citation><ArticleIdList><ArticleId IdType="doi">10.3109/00365548.2011.577094</ArticleId><ArticleId IdType="pubmed">21526904</ArticleId></ArticleIdList></Reference><Reference><Citation>Fischer TK, Nielsen AY, Sydenham TV, Andersen PH, Andersen B, Midgley SE. Emergence of enterovirus 71 C4a in Denmark, 2009 to 2013. Euro Surveill. 2014;19:20911. doi: 10.2807/1560-7917.ES2014.19.38.20911.</Citation><ArticleIdList><ArticleId IdType="doi">10.2807/1560-7917.ES2014.19.38.20911</ArticleId><ArticleId IdType="pubmed">25306878</ArticleId></ArticleIdList></Reference><Reference><Citation>Hassel C, Mirand A, Lukashev A, TerletskaiaLadwig E, Farkas A, Schuffenecker I, et al. Transmission patterns of human enterovirus 71 to, from and among European countries, 2003 to 2013. Euro Surveill. 2015;20:30005. doi: 10.2807/1560-7917.ES.2015.20.34.30005.</Citation><ArticleIdList><ArticleId IdType="doi">10.2807/1560-7917.ES.2015.20.34.30005</ArticleId><ArticleId IdType="pubmed">26530407</ArticleId></ArticleIdList></Reference><Reference><Citation>Akhmadishina LV, Govorukhina MV, Kovalev EV, Nenadskaya SA, Ivanova OE, Lukashev AN. Enterovirus A71 Meningoencephalitis Outbreak, Rostov-on-Don, Russia, 2013 - Volume 21, Number 8—August 2015 - Emerging Infectious Diseases journal - CDC. Emerg Infect Dis. 2015;21:1440–3. doi: 10.3201/eid2108.141084.</Citation><ArticleIdList><ArticleId IdType="doi">10.3201/eid2108.141084</ArticleId><ArticleId IdType="pmc">PMC4517719</ArticleId><ArticleId IdType="pubmed">26196217</ArticleId></ArticleIdList></Reference><Reference><Citation>Midgley SE, Nielsen AG, Trebbien R, Poulsen MW, Andersen PH, Fischer TK. Co-circulation of multiple subtypes of enterovirus A71 (EV- A71) genotype C, including novel recombinants characterised by use of whole genome sequencing (WGS), Denmark 2016. Euro Surveill. 2017;22:30565. doi: 10.2807/1560-7917.ES.2017.22.26.30565.</Citation><ArticleIdList><ArticleId IdType="doi">10.2807/1560-7917.ES.2017.22.26.30565</ArticleId><ArticleId IdType="pmc">PMC6518347</ArticleId><ArticleId IdType="pubmed">28681718</ArticleId></ArticleIdList></Reference><Reference><Citation>Wörner N, Rodrigo-García R, Antón A, Castellarnau E, Delgado I, Vazquez È, et al. Enterovirus-A71 Rhombencephalitis Outbreak in Catalonia: characteristics, management and outcome. Pediatr Infect Dis J. 2021;40:628–33. doi: 10.1097/INF.0000000000003114.</Citation><ArticleIdList><ArticleId IdType="doi">10.1097/INF.0000000000003114</ArticleId><ArticleId IdType="pmc">PMC8189429</ArticleId><ArticleId IdType="pubmed">34097655</ArticleId></ArticleIdList></Reference><Reference><Citation>Bian L, Wang Y, Yao X, Mao Q, Xu M, Liang Z. Coxsackievirus A6: a new emerging pathogen causing hand, foot and mouth disease outbreaks worldwide. Expert Rev Anti-Infect Ther. 2015;13:1061–71. doi: 10.1586/14787210.2015.1058156.</Citation><ArticleIdList><ArticleId IdType="doi">10.1586/14787210.2015.1058156</ArticleId><ArticleId IdType="pubmed">26112307</ArticleId></ArticleIdList></Reference><Reference><Citation>Noisumdaeng P, Korkusol A, Prasertsopon J, Sangsiriwut K, Chokephaibulkit K, Mungaomklang A, et al. Longitudinal study on enterovirus A71 and coxsackievirus A16 genotype/subgenotype replacements in hand, foot and mouth disease patients in Thailand, 2000–2017. Int J Infect Dis. 2019;80:84–91. doi: 10.1016/j.ijid.2018.12.020.</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.ijid.2018.12.020</ArticleId><ArticleId IdType="pubmed">30639624</ArticleId></ArticleIdList></Reference><Reference><Citation>Zhu P, Ji W, Li D, Li Z, Chen Y, Dai B, et al. Current status of hand-foot-and-mouth disease. J Biomed Sci. 2023;30:15. doi: 10.1186/s12929-023-00908-4.</Citation><ArticleIdList><ArticleId IdType="doi">10.1186/s12929-023-00908-4</ArticleId><ArticleId IdType="pmc">PMC9951172</ArticleId><ArticleId IdType="pubmed">36829162</ArticleId></ArticleIdList></Reference><Reference><Citation>Koh WM, Badaruddin H, La H, Chen MIC, Cook AR. Severity and burden of hand, foot and mouth disease in Asia: a modelling study. BMJ Glob Health. 2018;3:e000442. doi: 10.1136/bmjgh-2017-000442.</Citation><ArticleIdList><ArticleId IdType="doi">10.1136/bmjgh-2017-000442</ArticleId><ArticleId IdType="pmc">PMC5859810</ArticleId><ArticleId IdType="pubmed">29564154</ArticleId></ArticleIdList></Reference><Reference><Citation>Sadeuh-Mba SA, Joffret M-L, Mazitchi A, Endegue-Zanga M-C, Njouom R, Delpeyroux F, et al. Genetic and phenotypic characterization of recently discovered enterovirus D type 111. PLoS Negl Trop Dis. 2019;13:e0007797. doi: 10.1371/journal.pntd.0007797.</Citation><ArticleIdList><ArticleId IdType="doi">10.1371/journal.pntd.0007797</ArticleId><ArticleId IdType="pmc">PMC6818792</ArticleId><ArticleId IdType="pubmed">31622358</ArticleId></ArticleIdList></Reference><Reference><Citation>Bauer L, Lyoo H, van der Schaar HM, Strating JR, van Kuppeveld FJ. Direct-acting antivirals and host-targeting strategies to combat enterovirus infections. Curr Opin Virol. 2017;24:1–8. doi: 10.1016/j.coviro.2017.03.009.</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.coviro.2017.03.009</ArticleId><ArticleId IdType="pmc">PMC7172203</ArticleId><ArticleId IdType="pubmed">28411509</ArticleId></ArticleIdList></Reference><Reference><Citation>Wang J, Hu Y, Zheng M. Enterovirus A71 antivirals: past, present, and future. Acta Pharm Sin B. 2022;12:1542–66. doi: 10.1016/j.apsb.2021.08.017.</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.apsb.2021.08.017</ArticleId><ArticleId IdType="pmc">PMC9279511</ArticleId><ArticleId IdType="pubmed">35847514</ArticleId></ArticleIdList></Reference><Reference><Citation>Andino R, Kirkegaard K, Macadam A, Racaniello VR, Rosenfeld AB. The Picornaviridae family: knowledge gaps, animal models, countermeasures, and prototype pathogens. J Infect Dis. 2023;228:S427–45. doi: 10.1093/infdis/jiac426.</Citation><ArticleIdList><ArticleId IdType="doi">10.1093/infdis/jiac426</ArticleId><ArticleId IdType="pubmed">37849401</ArticleId></ArticleIdList></Reference><Reference><Citation>Liu Y, Zhou J, Ji G, Gao Y, Zhang C, Zhang T, et al. A novel subgenotype C6 Enterovirus A71 originating from the recombination between subgenotypes C4 and C2 strains in mainland China. Sci Rep. 2022;12:593. doi: 10.1038/s41598-021-04604-x.</Citation><ArticleIdList><ArticleId IdType="doi">10.1038/s41598-021-04604-x</ArticleId><ArticleId IdType="pmc">PMC8755819</ArticleId><ArticleId IdType="pubmed">35022489</ArticleId></ArticleIdList></Reference><Reference><Citation>Midgley SE, Benschop K, Dyrdak R, Mirand A, Bailly J-L, Bierbaum S, et al. Co-circulation of multiple enterovirus D68 subclades, including a novel B3 cluster, across Europe in a season of expected low prevalence, 2019/20. Euro Surveill. 2020;25:1900749. doi: 10.2807/1560-7917.ES.2020.25.2.1900749.</Citation><ArticleIdList><ArticleId IdType="doi">10.2807/1560-7917.ES.2020.25.2.1900749</ArticleId><ArticleId IdType="pmc">PMC6976881</ArticleId><ArticleId IdType="pubmed">31964463</ArticleId></ArticleIdList></Reference><Reference><Citation>Xie J, Yang X-H, Hu S-Q, Zhan W-L, Zhang C-B, Liu H, et al. Co-circulation of coxsackieviruses A-6, A-10, and A-16 causes hand, foot, and mouth disease in Guangzhou city China. BMC Infect Dis. 2020;20:271. doi: 10.1186/s12879-020-04992-x.</Citation><ArticleIdList><ArticleId IdType="doi">10.1186/s12879-020-04992-x</ArticleId><ArticleId IdType="pmc">PMC7137261</ArticleId><ArticleId IdType="pubmed">32264839</ArticleId></ArticleIdList></Reference><Reference><Citation>Junttila N, Lévêque N, Magnius LO, Kabue JP, Muyembe-Tamfum JJ, Maslin J, et al. Complete coding regions of the prototypes enterovirus B93 and C95: Phylogenetic analyses of the P1 and P3 regions of EV-B and EV-C strains. J Med Virol. 2015;87:485–97. doi: 10.1002/jmv.24062.</Citation><ArticleIdList><ArticleId IdType="doi">10.1002/jmv.24062</ArticleId><ArticleId IdType="pubmed">25163640</ArticleId></ArticleIdList></Reference><Reference><Citation>Lévêque N, Jacques J, Renois F, Antona D, Abely M, Chomel J-J, et al. Phylogenetic analysis of Echovirus 30 isolated during the 2005 outbreak in France reveals existence of multiple lineages and suggests frequent recombination events. J Clin Virol. 2010;48:137–41. doi: 10.1016/j.jcv.2010.03.011.</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.jcv.2010.03.011</ArticleId><ArticleId IdType="pubmed">20381415</ArticleId></ArticleIdList></Reference><Reference><Citation>Bouslama L, Nasri D, Chollet L, Belguith K, Bourlet T, Aouni M, et al. Natural Recombination Event within the Capsid Genomic Region Leading to a Chimeric Strain of Human Enterovirus B. J Virol. 2007;81:8944–52. doi: 10.1128/JVI.00180-07.</Citation><ArticleIdList><ArticleId IdType="doi">10.1128/JVI.00180-07</ArticleId><ArticleId IdType="pmc">PMC1951430</ArticleId><ArticleId IdType="pubmed">17537864</ArticleId></ArticleIdList></Reference><Reference><Citation>Lindberg AM, Andersson P, Savolainen C, Mulders MN, Hovi T. Evolution of the genome of Human enterovirus B: incongruence between phylogenies of the VP1 and 3CD regions indicates frequent recombination within the species. J Gen Virol. 2003;84:1223–35. doi: 10.1099/vir.0.18971-0.</Citation><ArticleIdList><ArticleId IdType="doi">10.1099/vir.0.18971-0</ArticleId><ArticleId IdType="pubmed">12692288</ArticleId></ArticleIdList></Reference><Reference><Citation>He W, Lu H, Song D, Zhao K, Gai X, Wang X, et al. The evidence of Coxsackievirus B3 induced myocarditis as the cause of death in a Sichuan snub-nosed monkey (Rhinopithecus roxellana) J Med Primatol. 2009;38:192–8. doi: 10.1111/j.1600-0684.2008.00336.x.</Citation><ArticleIdList><ArticleId IdType="doi">10.1111/j.1600-0684.2008.00336.x</ArticleId><ArticleId IdType="pubmed">19220685</ArticleId></ArticleIdList></Reference><Reference><Citation>He W, Lu H, Zhao K, Song D, Gai X, Gao F. Complete Genome Sequence of a Coxsackievirus B3 Isolated from a Sichuan Snub-Nosed Monkey. J Virol. 2012;86:13134–5. doi: 10.1128/JVI.02365-12.</Citation><ArticleIdList><ArticleId IdType="doi">10.1128/JVI.02365-12</ArticleId><ArticleId IdType="pmc">PMC3497664</ArticleId><ArticleId IdType="pubmed">23118460</ArticleId></ArticleIdList></Reference><Reference><Citation>Harvala H, Van Nguyen D, McIntyre C, Ahuka-Mundeke S, Ngole EM, Delaporte E, et al. Co-circulation of enteroviruses between apes and humans. J Gen Virol. 2014;95:403–7. doi: 10.1099/vir.0.059048-0.</Citation><ArticleIdList><ArticleId IdType="doi">10.1099/vir.0.059048-0</ArticleId><ArticleId IdType="pmc">PMC4093782</ArticleId><ArticleId IdType="pubmed">24189620</ArticleId></ArticleIdList></Reference><Reference><Citation>Harvala H, McIntyre CL, Imai N, Clasper L, Djoko CF, LeBreton M, et al. High Seroprevalence of enterovirus infections in apes and old world monkeys. Emerg Infect Dis. 2012;18:283–6. doi: 10.3201/eid1802.111363.</Citation><ArticleIdList><ArticleId IdType="doi">10.3201/eid1802.111363</ArticleId><ArticleId IdType="pmc">PMC3310466</ArticleId><ArticleId IdType="pubmed">22305156</ArticleId></ArticleIdList></Reference><Reference><Citation>Amona I, Medkour H, Akiana J, Davoust B, Tall ML, Grimaldier C, et al. Enteroviruses from humans and Great Apes in the Republic of Congo: recombination within enterovirus C serotypes. Microorganisms. 2020;8:1779. doi: 10.3390/microorganisms8111779.</Citation><ArticleIdList><ArticleId IdType="doi">10.3390/microorganisms8111779</ArticleId><ArticleId IdType="pmc">PMC7709013</ArticleId><ArticleId IdType="pubmed">33202777</ArticleId></ArticleIdList></Reference><Reference><Citation>Sereme Y, Zarza SM, Medkour H, Amona I, Fenollar F, Akiana J, et al. Stool serology: development of a Non-invasive immunological method for the detection of enterovirus-specific antibodies in Congo Gorilla Faeces. Microorganisms. 2021;9:810. doi: 10.3390/microorganisms9040810.</Citation><ArticleIdList><ArticleId IdType="doi">10.3390/microorganisms9040810</ArticleId><ArticleId IdType="pmc">PMC8068960</ArticleId><ArticleId IdType="pubmed">33921300</ArticleId></ArticleIdList></Reference><Reference><Citation>Sadeuh-Mba SA, Bessaud M, Joffret M-L, Endegue Zanga M-C, Balanant J, Mpoudi Ngole E, et al. Characterization of enteroviruses from non-human primates in Cameroon revealed virus types widespread in humans along with candidate new types and species. PLoS Negl Trop Dis. 2014;8:e3052. doi: 10.1371/journal.pntd.0003052.</Citation><ArticleIdList><ArticleId IdType="doi">10.1371/journal.pntd.0003052</ArticleId><ArticleId IdType="pmc">PMC4117447</ArticleId><ArticleId IdType="pubmed">25079078</ArticleId></ArticleIdList></Reference><Reference><Citation>Mombo IM, Berthet N, Lukashev AN, Bleicker T, Brünink S, Léger L, et al. First detection of an enterovirus C99 in a captive chimpanzee with acute flaccid paralysis, from the Tchimpounga Chimpanzee Rehabilitation Center Republic of Congo. PLoS One. 2015;10:e0136700. doi: 10.1371/journal.pone.0136700.</Citation><ArticleIdList><ArticleId IdType="doi">10.1371/journal.pone.0136700</ArticleId><ArticleId IdType="pmc">PMC4547728</ArticleId><ArticleId IdType="pubmed">26301510</ArticleId></ArticleIdList></Reference><Reference><Citation>Nguyen-Tran H, Park SW, Messacar K, Dominguez SR, Vogt MR, Permar S, et al. Enterovirus D68: a test case for the use of immunological surveillance to develop tools to mitigate the pandemic potential of emerging pathogens. Lancet Microbe. 2022;3:e83–5. doi: 10.1016/S2666-5247(21)00312-8.</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/S2666-5247(21)00312-8</ArticleId><ArticleId IdType="pmc">PMC8741221</ArticleId><ArticleId IdType="pubmed">35036969</ArticleId></ArticleIdList></Reference><Reference><Citation>Douek DC. PREMISE (Pandemic REsponse REpository through Microbial and Immune Surveillance and Epidemiology) program. https://www.niaid.nih.gov/research/premise. Accessed 12 Aug 2023.</Citation></Reference><Reference><Citation>Harvala H, Benschop KSM, Berginc N, Midgley S, Wolthers K, Simmonds P, et al. European Non-Polio Enterovirus Network: Introduction of Hospital-Based Surveillance Network to Understand the True Disease Burden of Non-Polio Enterovirus and Parechovirus Infections in Europe. Microorganisms. 2021;9:1827. doi: 10.3390/microorganisms9091827.</Citation><ArticleIdList><ArticleId IdType="doi">10.3390/microorganisms9091827</ArticleId><ArticleId IdType="pmc">PMC8469463</ArticleId><ArticleId IdType="pubmed">34576722</ArticleId></ArticleIdList></Reference><Reference><Citation>Chiu M-L, Luo S-T, Chen Y-Y, Chung WY, Duong V, Dussart P, et al. Establishment of Asia-Pacific Network for Enterovirus Surveillance. Vaccine. 2020;38:1–9. doi: 10.1016/j.vaccine.2019.09.111.</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.vaccine.2019.09.111</ArticleId><ArticleId IdType="pubmed">31679864</ArticleId></ArticleIdList></Reference><Reference><Citation>GPEI-Who we are. https://polioeradication.org/who-we-are/. Accessed 22 Sept 2023.</Citation></Reference><Reference><Citation>Ledford H. Spate of polio outbreaks worldwide puts scientists on alert. Nature. 2022;609:20–1. doi: 10.1038/d41586-022-02233-6.</Citation><ArticleIdList><ArticleId IdType="doi">10.1038/d41586-022-02233-6</ArticleId><ArticleId IdType="pubmed">35996010</ArticleId></ArticleIdList></Reference><Reference><Citation>Gebremedhin S, Shiferie F, Tsegaye DA, Alemayehu WA, Wondie T, Donofrio J, et al. Oral and inactivated polio vaccine coverage and determinants of coverage inequality among the most at-risk populations in Ethiopia. Am J Trop Med Hyg. 2023;109:1148–56. doi: 10.4269/ajtmh.23-0319.</Citation><ArticleIdList><ArticleId IdType="doi">10.4269/ajtmh.23-0319</ArticleId><ArticleId IdType="pmc">PMC10622460</ArticleId><ArticleId IdType="pubmed">37748762</ArticleId></ArticleIdList></Reference><Reference><Citation>GPEI: Polio Eradication Strategy 2022-2026, Geneva: World Health Organisation; 2021 Available at. https://polioeradication.org/gpei-strategy-2022-2026/</Citation></Reference><Reference><Citation>GPEI: Surveillance Indicators. https://polioeradication.org/polio-today/polio-now/surveillance-indicators/. Accessed 2 Dec 2023.</Citation></Reference><Reference><Citation>National Enterovirus Surveillance System (NESS) | CDC 2023. https://www.cdc.gov/surveillance/ness/index.html. Accessed 22 Sept 2023.</Citation></Reference><Reference><Citation>Protection AGD of HO of H. Australian National Enterovirus Reference Laboratory (ANERL) [poliovirus surveillance] annual reports. Available from https://www1.health.gov.au/internet/main/publishing.nsf/Content/cda-pubs-annlrpt-polioanrep.htm</Citation></Reference><Reference><Citation>Keeren K, Böttcher S, Diedrich S. Enterovirus Surveillance (EVSurv) in Germany. Microorganisms. 2021;9:2005. doi: 10.3390/microorganisms9102005.</Citation><ArticleIdList><ArticleId IdType="doi">10.3390/microorganisms9102005</ArticleId><ArticleId IdType="pmc">PMC8538599</ArticleId><ArticleId IdType="pubmed">34683328</ArticleId></ArticleIdList></Reference><Reference><Citation>Harvala H, Jasir A, Penttinen P, Pastore Celentano L, Greco D, Broberg E. Surveillance and laboratory detection for non-polio enteroviruses in the European Union/European Economic Area, 2016. Euro Surveill 2017;22. 10.2807/1560-7917.ES.2017.22.45.16-00807.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC5718392</ArticleId><ArticleId IdType="pubmed">29162204</ArticleId></ArticleIdList></Reference><Reference><Citation>Pogka V, Labropoulou S, Emmanouil M, Voulgari-Kokota A, Vernardaki A, Georgakopoulou T, et al. Laboratory surveillance of polio and other enteroviruses in high-risk populations and environmental samples. Appl Environ Microbiol. 2017;83:e02872–16. doi: 10.1128/AEM.02872-16.</Citation><ArticleIdList><ArticleId IdType="doi">10.1128/AEM.02872-16</ArticleId><ArticleId IdType="pmc">PMC5311404</ArticleId><ArticleId IdType="pubmed">28039136</ArticleId></ArticleIdList></Reference><Reference><Citation>Hampton LM. Immunization Systems Management Group of the Global Polio Eradication Initiative. Introduction of Inactivated Poliovirus Vaccine and Switch from Trivalent to Bivalent Oral Poliovirus Vaccine - Worldwide, 2013-2016. MMWR Morb Mortal Wkly Rep. 2015;64:699–702. Available at https://www.cdc.gov/mmwr/preview/mmwrhtml/mm6425a4.htm</Citation><ArticleIdList><ArticleId IdType="pmc">PMC4584682</ArticleId><ArticleId IdType="pubmed">26135591</ArticleId></ArticleIdList></Reference><Reference><Citation>Hampton LM. Cessation of Trivalent Oral Poliovirus Vaccine and Introduction of Inactivated Poliovirus Vaccine — Worldwide, 2016. MMWR Morb Mortal Wkly Rep. 2016;65. 10.15585/mmwr.mm6535a3.</Citation><ArticleIdList><ArticleId IdType="pubmed">27606675</ArticleId></ArticleIdList></Reference><Reference><Citation>Hib-DTaP-hepatitis B-poliovirus vaccine - GSK - AdisInsight. https://adis.springer.com/drugs/800004693 Accessed 17 Oct 2023.</Citation></Reference><Reference><Citation>Hib-DTaP-Hepatitis-B-Poliovirus-vaccine - Merck - AdisInsight. https://adis.springer.com/drugs/800037616. Accessed 17 Oct 2023.</Citation></Reference><Reference><Citation>Tregnaghi MW, Zambrano B, Santos-Lima E. Immunogenicity and Safety of an Investigational Hexavalent Diphtheria-tetanus-acellular Pertussis-inactivated Poliovirus-hepatitis B-Haemophilus influenzae B Conjugate Combined Vaccine in Healthy 2-, 4-, and 6-month-old Argentinean Infants. J Pediatr Infect Dis. 2011;30:e88. doi: 10.1097/INF.0b013e318212eb80.</Citation><ArticleIdList><ArticleId IdType="doi">10.1097/INF.0b013e318212eb80</ArticleId><ArticleId IdType="pubmed">21372751</ArticleId></ArticleIdList></Reference><Reference><Citation>WHO: Enterovirus 71 https://www.who.int/teams/health-product-policy-and-standards/standards-and-specifications/vaccine-standardization/enterovirus-71. Accessed 21 Sept 2023.</Citation></Reference><Reference><Citation>Li Y, Gao F, Wang Y, Li J, Zhang Y, Lv H, et al. Immunogenicity and safety of inactivated enterovirus A71 vaccines in children aged 6-35 months in China: a non-inferiority, randomised controlled trial. Lancet Reg Health West Pac. 2021;16. 10.1016/j.lanwpc.2021.100284.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC8579145</ArticleId><ArticleId IdType="pubmed">34881371</ArticleId></ArticleIdList></Reference><Reference><Citation>Snider CJ, Zaman K, Estivariz CF, Yunus M, Weldon WC, Wannemuehler KA, et al. Immunogenicity of full and fractional dose of inactivated poliovirus vaccine for use in routine immunisation and outbreak response: an open-label, randomised controlled trial. Lancet. 2019;393:2624–34. doi: 10.1016/S0140-6736(19)30503-3.</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/S0140-6736(19)30503-3</ArticleId><ArticleId IdType="pmc">PMC7069654</ArticleId><ArticleId IdType="pubmed">31104832</ArticleId></ArticleIdList></Reference><Reference><Citation>GlaxoSmithKline. Evaluation of GSK Biological’s dTpa-IPV Booster Vaccine in Children and Adolescents, 5 Years After Previous dTpa-IPV Boosting. Available at https://clinicaltrials.gov/study/NCT00635128</Citation></Reference><Reference><Citation>Hankaniemi MM, Laitinen OH, Stone VM, Sioofy-Khojine A, Maatta JAE, Larsson PG, et al. Optimized production and purification of Coxsackievirus B1 vaccine and its preclinical evaluation in a mouse model. Vaccine. 2017;35:3718–25. doi: 10.1016/j.vaccine.2017.05.057.</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.vaccine.2017.05.057</ArticleId><ArticleId IdType="pubmed">28579231</ArticleId></ArticleIdList></Reference><Reference><Citation>Hankaniemi MM, Stone VM, Sioofy-Khojine A-B, Heinimäki S, Marjomäki V, Hyöty H, et al. A comparative study of the effect of UV and formalin inactivation on the stability and immunogenicity of a Coxsackievirus B1 vaccine. Vaccine. 2019;37:5962–71. doi: 10.1016/j.vaccine.2019.08.037.</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.vaccine.2019.08.037</ArticleId><ArticleId IdType="pubmed">31471148</ArticleId></ArticleIdList></Reference><Reference><Citation>Stone VM, Hankaniemi MM, Svedin E, Sioofy-Khojine A, Oikarinen S, Hyoty H, et al. A Coxsackievirus B vaccine protects against virus-induced diabetes in an experimental mouse model of type 1 diabetes. Diabetologia. 2017 doi: 10.1007/s00125-017-4492-z.</Citation><ArticleIdList><ArticleId IdType="doi">10.1007/s00125-017-4492-z</ArticleId><ArticleId IdType="pmc">PMC6448957</ArticleId><ArticleId IdType="pubmed">29151123</ArticleId></ArticleIdList></Reference><Reference><Citation>Stone VM, Hankaniemi MM, Laitinen OH, Sioofy-Khojine AB, Lin A, Diaz Lozano IM, et al. A hexavalent Coxsackievirus B vaccine is highly immunogenic and has a strong protective capacity in mice and nonhuman primates. Sci Adv. 2020;6:eaaz2433. doi: 10.1126/sciadv.aaz2433.</Citation><ArticleIdList><ArticleId IdType="doi">10.1126/sciadv.aaz2433</ArticleId><ArticleId IdType="pmc">PMC7202868</ArticleId><ArticleId IdType="pubmed">32494709</ArticleId></ArticleIdList></Reference><Reference><Citation>Stone VM, Butrym M, Hankaniemi MM, Sioofy-Khojine A-B, Hytönen VP, Hyöty H, et al. Coxsackievirus B Vaccines Prevent Infection-Accelerated Diabetes in NOD Mice and Have No Disease-Inducing Effect. Diabetes. 2021;70:2871–8. doi: 10.2337/db21-0193.</Citation><ArticleIdList><ArticleId IdType="doi">10.2337/db21-0193</ArticleId><ArticleId IdType="pmc">PMC8660981</ArticleId><ArticleId IdType="pubmed">34497136</ArticleId></ArticleIdList></Reference><Reference><Citation>Stone VM, Utorova R, Butrym M, Sioofy-Khojine A-B, Hankaniemi MM, Ringqvist EE, et al. Coxsackievirus B infections are common in Cystic Fibrosis and experimental evidence supports protection by vaccination. iScience. 2022;25:105070. doi: 10.1016/j.isci.2022.105070.</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.isci.2022.105070</ArticleId><ArticleId IdType="pmc">PMC9490033</ArticleId><ArticleId IdType="pubmed">36157581</ArticleId></ArticleIdList></Reference><Reference><Citation>Hyöty H, Kääriäinen S, Laiho JE, Comer GM, Tian W, Härkönen T, et al. Safety, tolerability and immunogenicity of PRV-101, a multivalent vaccine targeting coxsackie B viruses (CVBs) associated with type 1 diabetes: a double-blind randomised placebo-controlled Phase I trial. Diabetologia. 2024 doi: 10.1007/s00125-024-06092-w.</Citation><ArticleIdList><ArticleId IdType="doi">10.1007/s00125-024-06092-w</ArticleId><ArticleId IdType="pmc">PMC10954874</ArticleId><ArticleId IdType="pubmed">38369573</ArticleId></ArticleIdList></Reference><Reference><Citation>Yeh MT, Bujaki E, Dolan PT, Smith M, Wahid R, Konz J, et al. Engineering the live-attenuated polio vaccine to prevent reversion to virulence. Cell Host Microbe. 2020;27:736–751.e8. doi: 10.1016/j.chom.2020.04.003.</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.chom.2020.04.003</ArticleId><ArticleId IdType="pmc">PMC7566161</ArticleId><ArticleId IdType="pubmed">32330425</ArticleId></ArticleIdList></Reference><Reference><Citation>WHO: First ever vaccine listed under WHO emergency use https://www.who.int/news/item/13-11-2020-first-ever-vaccine-listed-under-who-emergency-use. Accessed 7 Dec 2023.</Citation></Reference><Reference><Citation>WHO: Poliovirus vaccines https://www.who.int/groups/global-advisory-committee-on-vaccine-safety/topics/poliovirus-vaccines. Accessed 7 Dec 2023.</Citation></Reference><Reference><Citation>Davlantes E. Notes from the Field: Circulating Vaccine-Derived Poliovirus Type 2 Emergences Linked to Novel Oral Poliovirus Vaccine Type 2 Use — Six African Countries, 2021–2023. MMWR Morb Mortal Wkly Rep. 2023;72. 10.15585/mmwr.mm7238a4.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC10519714</ArticleId><ArticleId IdType="pubmed">37733626</ArticleId></ArticleIdList></Reference><Reference><Citation>Yeh MT, Smith M, Carlyle S, Konopka-Anstadt JL, Burns CC, Konz J, et al. Genetic stabilization of attenuated oral vaccines against poliovirus types 1 and 3. Nature. 2023;619:135–42. doi: 10.1038/s41586-023-06212-3.</Citation><ArticleIdList><ArticleId IdType="doi">10.1038/s41586-023-06212-3</ArticleId><ArticleId IdType="pmc">PMC10322712</ArticleId><ArticleId IdType="pubmed">37316671</ArticleId></ArticleIdList></Reference><Reference><Citation>Liu X, Chang S, Wang R, Xiao Y, Li F, Xu Q, et al. Immunogenicity and Safety of an Inactivated Enterovirus 71 Vaccine Administered Simultaneously with Hepatitis B Virus Vaccine, Group A Meningococcal Polysaccharide Vaccine, Measles-Rubella Combined Vaccine and Japanese Encephalitis Vaccine: A Multi-Center, Randomized Controlled Clinical Trial in China. Vaccines (Basel) 2022;10:895. doi: 10.3390/vaccines10060895.</Citation><ArticleIdList><ArticleId IdType="doi">10.3390/vaccines10060895</ArticleId><ArticleId IdType="pmc">PMC9230521</ArticleId><ArticleId IdType="pubmed">35746502</ArticleId></ArticleIdList></Reference><Reference><Citation>Lee S, Nguyen MT, Currier MG, Jenkins JB, Strobert EA, Kajon AE, et al. A polyvalent inactivated rhinovirus vaccine is broadly immunogenic in rhesus macaques. Nat Commun. 2016;7:12838. doi: 10.1038/ncomms12838.</Citation><ArticleIdList><ArticleId IdType="doi">10.1038/ncomms12838</ArticleId><ArticleId IdType="pmc">PMC5036149</ArticleId><ArticleId IdType="pubmed">27653379</ArticleId></ArticleIdList></Reference><Reference><Citation>Mone K, Lasrado N, Sur M, Reddy J. Vaccines against Group B Coxsackieviruses and Their Importance. Vaccines. 2023;11:274. doi: 10.3390/vaccines11020274.</Citation><ArticleIdList><ArticleId IdType="doi">10.3390/vaccines11020274</ArticleId><ArticleId IdType="pmc">PMC9961666</ArticleId><ArticleId IdType="pubmed">36851152</ArticleId></ArticleIdList></Reference><Reference><Citation>Bello AM, Roshorm YM. Recent progress and advances towards developing enterovirus 71 vaccines for effective protection against human hand, foot and mouth disease (HFMD) Biologicals. 2022;79:1–9. doi: 10.1016/j.biologicals.2022.08.007.</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.biologicals.2022.08.007</ArticleId><ArticleId IdType="pubmed">36089444</ArticleId></ArticleIdList></Reference><Reference><Citation>Fang C-Y, Liu C-C. Recent development of enterovirus A vaccine candidates for the prevention of hand, foot, and mouth disease. Expert Rev Vacc. 2018;17:819–31. doi: 10.1080/14760584.2018.1510326.</Citation><ArticleIdList><ArticleId IdType="doi">10.1080/14760584.2018.1510326</ArticleId><ArticleId IdType="pubmed">30095317</ArticleId></ArticleIdList></Reference><Reference><Citation>Hankaniemi MM, Stone VM, Andrejeff T, Heinimäki S, Sioofy-Khojine A-B, Marjomäki V, et al. Formalin treatment increases the stability and immunogenicity of coxsackievirus B1 VLP vaccine. Antiviral Res. 2019;171:104595. doi: 10.1016/j.antiviral.2019.104595.</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.antiviral.2019.104595</ArticleId><ArticleId IdType="pubmed">31491431</ArticleId></ArticleIdList></Reference><Reference><Citation>Hankaniemi MM, Baikoghli MA, Stone VM, Xing L, Vaatainen O, Soppela S, et al. Structural Insight into CVB3-VLP Non-Adjuvanted Vaccine. Microorganisms. 2020;8: 10.3390/microorganisms8091287.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC7565060</ArticleId><ArticleId IdType="pubmed">32846899</ArticleId></ArticleIdList></Reference><Reference><Citation>Wahid R, Cannon MJ, Chow M. Virus-Specific CD4+ and CD8+ cytotoxic T-cell responses and long-term T-cell memory in individuals vaccinated against polio. J Virol. 2005;79:5988–95. doi: 10.1128/JVI.79.10.5988-5995.2005.</Citation><ArticleIdList><ArticleId IdType="doi">10.1128/JVI.79.10.5988-5995.2005</ArticleId><ArticleId IdType="pmc">PMC1091702</ArticleId><ArticleId IdType="pubmed">15857985</ArticleId></ArticleIdList></Reference><Reference><Citation>Kasstan B, Mounier-Jack S, Chantler T, Masters N, Flores SA, Stokley S, et al. Poliovirus outbreak in New York State, August 2022: qualitative assessment of immediate public health responses and priorities for improving vaccine coverage. Epidemiol Infect. 2023;151:e120. doi: 10.1017/S0950268823001127.</Citation><ArticleIdList><ArticleId IdType="doi">10.1017/S0950268823001127</ArticleId><ArticleId IdType="pmc">PMC10468811</ArticleId><ArticleId IdType="pubmed">37435800</ArticleId></ArticleIdList></Reference><Reference><Citation>Zhang W, Dai W, Zhang C, Zhou Y, Xiong P, Wang S, et al. A virus-like particle-based tetravalent vaccine for hand, foot, and mouth disease elicits broad and balanced protective immunity. Emerg Microbes Infect. 2018;7:94. doi: 10.1038/s41426-018-0094-1.</Citation><ArticleIdList><ArticleId IdType="doi">10.1038/s41426-018-0094-1</ArticleId><ArticleId IdType="pmc">PMC5959873</ArticleId><ArticleId IdType="pubmed">29777102</ArticleId></ArticleIdList></Reference><Reference><Citation>Lim P-Y, Hickey AC, Jamiluddin MF, Hamid S, Kramer J, Santos R, et al. Immunogenicity and performance of an enterovirus 71 virus-like-particle vaccine in nonhuman primates. Vaccine. 2015;33:6017–24. doi: 10.1016/j.vaccine.2015.05.108.</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.vaccine.2015.05.108</ArticleId><ArticleId IdType="pubmed">26271825</ArticleId></ArticleIdList></Reference><Reference><Citation>Wu CN, Lin YC, Fann C, Liao NS, Shih SR, Ho MS. Protection against lethal enterovirus 71 infection in newborn mice by passive immunization with subunit VP1 vaccines and inactivated virus. Vaccine. 2001;20:895–904. doi: 10.1016/s0264-410x(01)00385-1.</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/s0264-410x(01)00385-1</ArticleId><ArticleId IdType="pubmed">11738755</ArticleId></ArticleIdList></Reference><Reference><Citation>Tsou Y-L, Lin Y-W, Shao H-Y, Yu S-L, Wu S-R, Lin H-Y, et al. Recombinant adeno-vaccine expressing enterovirus 71-like particles against hand, foot, and mouth disease. PLoS Negl Trop Dis. 2015;9:e0003692. doi: 10.1371/journal.pntd.0003692.</Citation><ArticleIdList><ArticleId IdType="doi">10.1371/journal.pntd.0003692</ArticleId><ArticleId IdType="pmc">PMC4391779</ArticleId><ArticleId IdType="pubmed">25855976</ArticleId></ArticleIdList></Reference><Reference><Citation>Sekaly R-P. The failed HIV Merck vaccine study: a step back or a launching point for future vaccine development? J Exp Med. 2008;205:7–12. doi: 10.1084/jem.20072681.</Citation><ArticleIdList><ArticleId IdType="doi">10.1084/jem.20072681</ArticleId><ArticleId IdType="pmc">PMC2234358</ArticleId><ArticleId IdType="pubmed">18195078</ArticleId></ArticleIdList></Reference><Reference><Citation>Tung WS, Bakar SA, Sekawi Z, Rosli R. DNA vaccine constructs against enterovirus 71 elicit immune response in mice. Genet Vaccines Ther. 2007;5:6. doi: 10.1186/1479-0556-5-6.</Citation><ArticleIdList><ArticleId IdType="doi">10.1186/1479-0556-5-6</ArticleId><ArticleId IdType="pmc">PMC3225814</ArticleId><ArticleId IdType="pubmed">17445254</ArticleId></ArticleIdList></Reference><Reference><Citation>Kimura T, Leal JM, Simpson A, Warner NL, Berube BJ, Archer JF, et al. A localizing nanocarrier formulation enables multi-target immune responses to multivalent replicating RNA with limited systemic inflammation. Mol Ther. 2023;31:2360–75. doi: 10.1016/j.ymthe.2023.06.017.</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.ymthe.2023.06.017</ArticleId><ArticleId IdType="pmc">PMC10422015</ArticleId><ArticleId IdType="pubmed">37403357</ArticleId></ArticleIdList></Reference><Reference><Citation>Zhang C, Zhang Y, Li Y, Lu J, Xiong S, Yue Y. Exosome-based delivery of VP1 protein conferred enhanced resistance of mice to CVB3-induced viral myocarditis. Virology. 2023;579:46–53. doi: 10.1016/j.virol.2022.12.015.</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.virol.2022.12.015</ArticleId><ArticleId IdType="pubmed">36603532</ArticleId></ArticleIdList></Reference><Reference><Citation>Shen C, Liu Q, Zhou Y, Ku Z, Wang L, Lan K, et al. Inactivated coxsackievirus A10 experimental vaccines protect mice against lethal viral challenge. Vaccine. 2016;34:5005–12. doi: 10.1016/j.vaccine.2016.08.033.</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.vaccine.2016.08.033</ArticleId><ArticleId IdType="pubmed">27562093</ArticleId></ArticleIdList></Reference><Reference><Citation>Jin W-P, Lu J, Zhang X-Y, Wu J, Wei Z-N, Mai J-Y, et al. Efficacy of Coxsackievirus A5 Vaccine Candidates in an Actively Immunized Mouse Model. J Virol. 2021;95:10.1128/jvi.01743-20.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC8094937</ArticleId><ArticleId IdType="pubmed">33408178</ArticleId></ArticleIdList></Reference><Reference><Citation>Zhang Z, Dong Z, Wang Q, Carr MJ, Li J, Liu T, et al. Characterization of an inactivated whole-virus bivalent vaccine that induces balanced protective immunity against coxsackievirus A6 and A10 in mice. Vaccine. 2018;36:7095–104. doi: 10.1016/j.vaccine.2018.09.069.</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.vaccine.2018.09.069</ArticleId><ArticleId IdType="pubmed">30316529</ArticleId></ArticleIdList></Reference><Reference><Citation>Sun Y-S, Xia Y, Xu F, Lu H-J, Mao Z-A, Gao M, et al. Development and evaluation of an inactivated coxsackievirus A16 vaccine in gerbils. Emerg Microbes Infect. 11:1994–2006. 10.1080/22221751.2022.2093132.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC9377242</ArticleId><ArticleId IdType="pubmed">35787233</ArticleId></ArticleIdList></Reference><Reference><Citation>Hu G, Jin W-P, Yang Z-H, Lv S-Y, Wu J, Yu Y-T, et al. Efficacy of Coxsackievirus A2 vaccine candidates correlating to humoral immunity in mice challenged with a mouse-adapted strain. Vaccine. 2022;40:4716–25. doi: 10.1016/j.vaccine.2022.06.021.</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.vaccine.2022.06.021</ArticleId><ArticleId IdType="pubmed">35760737</ArticleId></ArticleIdList></Reference><Reference><Citation>Raychoudhuri A, Naru AK, Kanubothula SR, Uddala R. Development of an experimental inactivated vaccine from Vero cell adapted Enterovirus D68. Virus Res. 2021;304:198528. doi: 10.1016/j.virusres.2021.198528.</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.virusres.2021.198528</ArticleId><ArticleId IdType="pubmed">34339771</ArticleId></ArticleIdList></Reference><Reference><Citation>Yee PTI, Tan SH, Ong KC, Tan KO, Wong KT, Hassan SS, et al. Development of live attenuated Enterovirus 71 vaccine strains that confer protection against lethal challenge in mice. Sci Rep. 2019;9:4805. doi: 10.1038/s41598-019-41285-z.</Citation><ArticleIdList><ArticleId IdType="doi">10.1038/s41598-019-41285-z</ArticleId><ArticleId IdType="pmc">PMC6423319</ArticleId><ArticleId IdType="pubmed">30886246</ArticleId></ArticleIdList></Reference><Reference><Citation>Meng T, Wong S-M, Chua K-B. A Novel Attenuated Enterovirus A71 Mutant with VP1-V238A,K244R Exhibits Reduced Efficiency of Cell Entry/Exit and Augmented Binding Affinity to Sulfated Glycans. J Virol. 2021;95:10.1128/jvi.01055-21. 10.1128/jvi.01055-21.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC8549518</ArticleId><ArticleId IdType="pubmed">34468173</ArticleId></ArticleIdList></Reference><Reference><Citation>Wang R, Sun Q, Xiao J, Wang C, Li X, Li J, et al. Effects of glycine 64 substitutions in RNA-dependent RNA polymerase on ribavirin sensitivity and pathogenicity of coxsackievirus A6. Virus Res. 2023;339:199268. doi: 10.1016/j.virusres.2023.199268.</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.virusres.2023.199268</ArticleId><ArticleId IdType="pmc">PMC10685073</ArticleId><ArticleId IdType="pubmed">37949376</ArticleId></ArticleIdList></Reference><Reference><Citation>Yang Z, Gao F, Wang X, Shi L, Zhou Z, Jiang Y, et al. Development and characterization of an enterovirus 71 (EV71) virus-like particles (VLPs) vaccine produced in Pichia pastoris. Hum Vaccin Immunother. n.d.;16:1602–10. 10.1080/21645515.2019.1649554.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC7482752</ArticleId><ArticleId IdType="pubmed">31403352</ArticleId></ArticleIdList></Reference><Reference><Citation>Zhou Y, Shen C, Zhang C, Zhang W, Wang L, Lan K, et al. Yeast-produced recombinant virus-like particles of coxsackievirus A6 elicited protective antibodies in mice. Antiviral Res. 2016;132:165–9. doi: 10.1016/j.antiviral.2016.06.004.</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.antiviral.2016.06.004</ArticleId><ArticleId IdType="pubmed">27315772</ArticleId></ArticleIdList></Reference><Reference><Citation>Zhou Y, Zhang C, Liu Q, Gong S, Geng L, Huang Z. A virus-like particle vaccine protects mice against coxsackievirus A10 lethal infection. Antiviral Res. 2018;152:124–30. doi: 10.1016/j.antiviral.2018.02.016.</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.antiviral.2018.02.016</ArticleId><ArticleId IdType="pubmed">29470994</ArticleId></ArticleIdList></Reference><Reference><Citation>Krug PW, Wang L, Shi W, Kong W-P, Moss DL, Yang ES, et al. EV-D68 virus-like particle vaccines elicit cross-clade neutralizing antibodies that inhibit infection and block dissemination. Sci Adv. 2023;9:eadg6076. doi: 10.1126/sciadv.adg6076.</Citation><ArticleIdList><ArticleId IdType="doi">10.1126/sciadv.adg6076</ArticleId><ArticleId IdType="pmc">PMC10191429</ArticleId><ArticleId IdType="pubmed">37196074</ArticleId></ArticleIdList></Reference><Reference><Citation>Zhang C, Zhang X, Zhang W, Dai W, Xie J, Ye L, et al. Enterovirus D68 virus-like particles expressed in Pichia pastoris potently induce neutralizing antibody responses and confer protection against lethal viral infection in mice. Emerg Microbes Infect. 2018;7:3. doi: 10.1038/s41426-017-0005-x.</Citation><ArticleIdList><ArticleId IdType="doi">10.1038/s41426-017-0005-x</ArticleId><ArticleId IdType="pmc">PMC5837163</ArticleId><ArticleId IdType="pubmed">29323105</ArticleId></ArticleIdList></Reference><Reference><Citation>Urakawa T, Ferguson M, Minor PD, Cooper J, Sullivan M, Almond JW, et al. Synthesis of Immunogenic, but Non-infectious, Poliovirus Particles in Insect Cells by a Baculovirus Expression Vector. J Gen Virol. 1989;70:1453–63. doi: 10.1099/0022-1317-70-6-1453.</Citation><ArticleIdList><ArticleId IdType="doi">10.1099/0022-1317-70-6-1453</ArticleId><ArticleId IdType="pubmed">2543785</ArticleId></ArticleIdList></Reference><Reference><Citation>Rombaut B, Jore JP. Immunogenic, non-infectious polio subviral particles synthesized in Saccharomyces cerevisiae. J Gen Virol. 1997;78(Pt 8):1829–32. doi: 10.1099/0022-1317-78-8-1829.</Citation><ArticleIdList><ArticleId IdType="doi">10.1099/0022-1317-78-8-1829</ArticleId><ArticleId IdType="pubmed">9266976</ArticleId></ArticleIdList></Reference><Reference><Citation>Frietze KM, Peabody DS, Chackerian B. Engineering virus-like particles as vaccine platforms. Curr Opin Virol. 2016;18:44–9. doi: 10.1016/j.coviro.2016.03.001.</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.coviro.2016.03.001</ArticleId><ArticleId IdType="pmc">PMC4983494</ArticleId><ArticleId IdType="pubmed">27039982</ArticleId></ArticleIdList></Reference><Reference><Citation>Rohovie M, Nagasawaa M, Swartz J. Virus-like particles: Next-generation nanoparticles for targeted therapeutic delivery. Bioeng Transl Med. 2016;2:43–57. doi: 10.1002/btm2.10049.</Citation><ArticleIdList><ArticleId IdType="doi">10.1002/btm2.10049</ArticleId><ArticleId IdType="pmc">PMC5689521</ArticleId><ArticleId IdType="pubmed">29313023</ArticleId></ArticleIdList></Reference><Reference><Citation>Adeyemi OO, Nicol C, Stonehouse NJ, Rowlands DJ. Increasing Type 1 Poliovirus Capsid Stability by Thermal Selection. J Virol. 2017;91:e01586–16. doi: 10.1128/JVI.01586-16.</Citation><ArticleIdList><ArticleId IdType="doi">10.1128/JVI.01586-16</ArticleId><ArticleId IdType="pmc">PMC5286869</ArticleId><ArticleId IdType="pubmed">27928008</ArticleId></ArticleIdList></Reference><Reference><Citation>Fox H, Knowlson S, Minor PD, Macadam AJ. Genetically thermo-stabilised, immunogenic poliovirus empty capsids; a strategy for non-replicating vaccines. PLoS Pathog. 2017;13:e1006117. doi: 10.1371/journal.ppat.1006117.</Citation><ArticleIdList><ArticleId IdType="doi">10.1371/journal.ppat.1006117</ArticleId><ArticleId IdType="pmc">PMC5245777</ArticleId><ArticleId IdType="pubmed">28103317</ArticleId></ArticleIdList></Reference><Reference><Citation>Xu Y, Ma S, Huang Y, Chen F, Chen L, Ding D, et al. Virus-like particle vaccines for poliovirus types 1, 2, and 3 with enhanced thermostability expressed in insect cells. Vaccine. 2019;37:2340–7. doi: 10.1016/j.vaccine.2019.03.031.</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.vaccine.2019.03.031</ArticleId><ArticleId IdType="pubmed">30922699</ArticleId></ArticleIdList></Reference><Reference><Citation>Sherry L, Bahar MW, Porta C, Fox H, Grehan K, Nasta V, et al. Risk-free polio vaccine: Recombinant expression systems for production of stabilised virus-like particles 2024. bioRxiv 2024.05.13.593909; 10.1101/2024.05.13.593909.</Citation></Reference><Reference><Citation>Buzas EI. The roles of extracellular vesicles in the immune system. Nat Rev Immunol. 2023;23:236–50. doi: 10.1038/s41577-022-00763-8.</Citation><ArticleIdList><ArticleId IdType="doi">10.1038/s41577-022-00763-8</ArticleId><ArticleId IdType="pmc">PMC9361922</ArticleId><ArticleId IdType="pubmed">35927511</ArticleId></ArticleIdList></Reference><Reference><Citation>Gao Y, Yue Y, Xiong S. An Albumin-Binding Domain Peptide Confers Enhanced Immunoprotection Against Viral Myocarditis by CVB3 VP1 Vaccine. Front Immunol. 2021;12. 10.3389/fimmu.2021.666594.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC8492941</ArticleId><ArticleId IdType="pubmed">34630378</ArticleId></ArticleIdList></Reference><Reference><Citation>Emini EA, Jameson BA, Wimmer E. Priming for and induction of anti-poliovirus neutralizing antibodies by synthetic peptides. Nature. 1983;304:699–703. doi: 10.1038/304699a0.</Citation><ArticleIdList><ArticleId IdType="doi">10.1038/304699a0</ArticleId><ArticleId IdType="pubmed">6310403</ArticleId></ArticleIdList></Reference><Reference><Citation>Puligedda RD, Kouiavskaia D, Al-Saleem FH, Kattala CD, Nabi U, Yaqoob H, et al. Characterization of human monoclonal antibodies that neutralize multiple poliovirus serotypes. Vaccine. 2017;35:5455–62. doi: 10.1016/j.vaccine.2017.03.038.</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.vaccine.2017.03.038</ArticleId><ArticleId IdType="pubmed">28343771</ArticleId></ArticleIdList></Reference><Reference><Citation>Kidd S, Lopez AS, Konopka-Anstadt JL, Nix WA, Routh JA, Oberste MS. Enterovirus D68–associated acute flaccid myelitis, United States, 2020. Emerg Infect Dis. 2020;26:e201630. doi: 10.3201/eid2610.201630.</Citation><ArticleIdList><ArticleId IdType="doi">10.3201/eid2610.201630</ArticleId><ArticleId IdType="pmc">PMC7510737</ArticleId><ArticleId IdType="pubmed">32833616</ArticleId></ArticleIdList></Reference><Reference><Citation>He F, Rui J, Deng Z, Zhang Y, Qian K, Zhu C, et al. Surveillance, Epidemiology and Impact of EV-A71 Vaccination on Hand, Foot, and Mouth Disease in Nanchang, China, 2010–2019. Front Microbiol. 2022;12. 10.3389/fmicb.2021.811553.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC8770912</ArticleId><ArticleId IdType="pubmed">35069515</ArticleId></ArticleIdList></Reference><Reference><Citation>Lim HX, Poh CL. Insights into innate and adaptive immune responses in vaccine development against EV-A71. Ther Adv Vaccines Immunother. 2019;7:2515135519888998. doi: 10.1177/2515135519888998.</Citation><ArticleIdList><ArticleId IdType="doi">10.1177/2515135519888998</ArticleId><ArticleId IdType="pmc">PMC6873268</ArticleId><ArticleId IdType="pubmed">31799495</ArticleId></ArticleIdList></Reference><Reference><Citation>Chang L-Y, Hsiung CA, Lu C-Y, Lin T-Y, Huang F-Y, Lai Y-H, et al. Status of cellular rather than humoral immunity is correlated with clinical outcome of enterovirus 71. Pediatr Res. 2006;60:466–71. doi: 10.1203/01.pdr.0000238247.86041.19.</Citation><ArticleIdList><ArticleId IdType="doi">10.1203/01.pdr.0000238247.86041.19</ArticleId><ArticleId IdType="pmc">PMC7086547</ArticleId><ArticleId IdType="pubmed">16940249</ArticleId></ArticleIdList></Reference><Reference><Citation>Brickley EB, Wieland-Alter W, Connor RI, Ackerman ME, Boesch AW, Arita M, et al. Intestinal Immunity to poliovirus following sequential trivalent inactivated polio vaccine/bivalent oral polio vaccine and trivalent inactivated polio vaccine-only immunization schedules: analysis of an open-label, randomized, controlled trial in Chilean infants. Clin Infect Dis. 2018;67:S42–50. doi: 10.1093/cid/ciy603.</Citation><ArticleIdList><ArticleId IdType="doi">10.1093/cid/ciy603</ArticleId><ArticleId IdType="pmc">PMC6206105</ArticleId><ArticleId IdType="pubmed">30376086</ArticleId></ArticleIdList></Reference><Reference><Citation>Gaevert JA, Luque Duque D, Lythe G, Molina-París C, Thomas PG. Quantifying T cell cross-reactivity: influenza and coronaviruses. Viruses. 2021;13:1786. doi: 10.3390/v13091786.</Citation><ArticleIdList><ArticleId IdType="doi">10.3390/v13091786</ArticleId><ArticleId IdType="pmc">PMC8472275</ArticleId><ArticleId IdType="pubmed">34578367</ArticleId></ArticleIdList></Reference><Reference><Citation>Mohn KGI, Brokstad KA, Islam S, Oftung F, Tøndel C, Aarstad HJ, et al. Early induction of cross-reactive CD8+ T-cell responses in tonsils after live-attenuated influenza vaccination in children. J Infect Dis. 2020;221:1528–37. doi: 10.1093/infdis/jiz583.</Citation><ArticleIdList><ArticleId IdType="doi">10.1093/infdis/jiz583</ArticleId><ArticleId IdType="pmc">PMC7137893</ArticleId><ArticleId IdType="pubmed">32255493</ArticleId></ArticleIdList></Reference><Reference><Citation>Oberhardt V, Luxenburger H, Kemming J, Schulien I, Ciminski K, Giese S, et al. Rapid and stable mobilization of CD8+ T cells by SARS-CoV-2 mRNA vaccine. Nature. 2021;597:268–73. doi: 10.1038/s41586-021-03841-4.</Citation><ArticleIdList><ArticleId IdType="doi">10.1038/s41586-021-03841-4</ArticleId><ArticleId IdType="pmc">PMC8426185</ArticleId><ArticleId IdType="pubmed">34320609</ArticleId></ArticleIdList></Reference><Reference><Citation>Chen M, Venturi V, Munier CML. Dissecting the protective effect of CD8+ T cells in response to SARS-CoV-2 mRNA vaccination and the potential link with lymph node CD8+ T CELLS. Biology. 2023;12:1035. doi: 10.3390/biology12071035.</Citation><ArticleIdList><ArticleId IdType="doi">10.3390/biology12071035</ArticleId><ArticleId IdType="pmc">PMC10376827</ArticleId><ArticleId IdType="pubmed">37508464</ArticleId></ArticleIdList></Reference><Reference><Citation>Rosenfeld AB, Shen EQL, Melendez M, Mishra N, Lipkin WI, Racaniello VR. Cross-reactive antibody responses against nonpoliovirus enteroviruses. Bio. 2022;13:e03660–21. doi: 10.1128/mbio.03660-21.</Citation><ArticleIdList><ArticleId IdType="doi">10.1128/mbio.03660-21</ArticleId><ArticleId IdType="pmc">PMC8764532</ArticleId><ArticleId IdType="pubmed">35038922</ArticleId></ArticleIdList></Reference><Reference><Citation>Pupina N, Avarlaid A, Sadam H, Pihlak A, Jaago M, Tuvikene J, et al. Immune response to a conserved enteroviral epitope of the major capsid VP1 protein is associated with lower risk of cardiovascular disease. EBioMedicine. 2022;76:103835. doi: 10.1016/j.ebiom.2022.103835.</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.ebiom.2022.103835</ArticleId><ArticleId IdType="pmc">PMC8801986</ArticleId><ArticleId IdType="pubmed">35091341</ArticleId></ArticleIdList></Reference><Reference><Citation>Beck MA, Tracy SM. Evidence for a group-specific enteroviral antigen(s) recognized by human T cells. J Clin Microbiol. 1990;28:1822–7. doi: 10.1128/jcm.28.8.1822-1827.1990.</Citation><ArticleIdList><ArticleId IdType="doi">10.1128/jcm.28.8.1822-1827.1990</ArticleId><ArticleId IdType="pmc">PMC268054</ArticleId><ArticleId IdType="pubmed">1975596</ArticleId></ArticleIdList></Reference><Reference><Citation>Graham S, Wang EC, Jenkins O, Borysiewicz LK. Analysis of the human T-cell response to picornaviruses: identification of T-cell epitopes close to B-cell epitopes in poliovirus. J Virol. 1993;67:1627–37. doi: 10.1128/jvi.67.3.1627-1637.1993.</Citation><ArticleIdList><ArticleId IdType="doi">10.1128/jvi.67.3.1627-1637.1993</ArticleId><ArticleId IdType="pmc">PMC237534</ArticleId><ArticleId IdType="pubmed">7679749</ArticleId></ArticleIdList></Reference><Reference><Citation>Vecchio F, Carré A, Korenkov D, Zhou Z, Apaolaza P, Tuomela S, et al. Coxsackievirus infection induces direct pancreatic β-cell killing but poor anti-viral CD8+ T-cell responses. bioRxiv. 2023.08.19.553954. 10.1101/2023.08.19.553954.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC10917340</ArticleId><ArticleId IdType="pubmed">38446892</ArticleId></ArticleIdList></Reference><Reference><Citation>Liu P, Yuan Y, Cui B, Huo Y, Bian L, Chen L, et al. Cross-Antigenicity between EV71 Sub-Genotypes: Implications for Vaccine Efficacy. Viruses. 2021;13:720. doi: 10.3390/v13050720.</Citation><ArticleIdList><ArticleId IdType="doi">10.3390/v13050720</ArticleId><ArticleId IdType="pmc">PMC8143144</ArticleId><ArticleId IdType="pubmed">33919184</ArticleId></ArticleIdList></Reference><Reference><Citation>Paul JR, Trask JD. The neutralization test in poliomyelitis : comparative results with four strains of the virus. J Exp Med. 1935;61:447–64. doi: 10.1084/jem.61.4.447.</Citation><ArticleIdList><ArticleId IdType="doi">10.1084/jem.61.4.447</ArticleId><ArticleId IdType="pmc">PMC2133235</ArticleId><ArticleId IdType="pubmed">19870370</ArticleId></ArticleIdList></Reference><Reference><Citation>Stewart FW, Rhoads CP. Intradermal versus subcutaneous immunization of monkeys against poliomyelitis. J Exp Med. 1929;49:959–73. doi: 10.1084/jem.49.6.959.</Citation><ArticleIdList><ArticleId IdType="doi">10.1084/jem.49.6.959</ArticleId><ArticleId IdType="pmc">PMC2131593</ArticleId><ArticleId IdType="pubmed">19869595</ArticleId></ArticleIdList></Reference><Reference><Citation>Burnet FM, Macnamara J. Immunological Differences Between Strains of Poliomyelitic Virus. Br J Exp Pathol. 1931;12:57–61. Available at https://www.ncbi.nlm.nih.gov/pmc/articles/PMC2048137/.</Citation></Reference><Reference><Citation>Chen Z, Fischer ER, Kouiavskaia D, Hansen BT, Ludtke SJ, Bidzhieva B, et al. Cross-neutralizing human anti-poliovirus antibodies bind the recognition site for cellular receptor. Proc Natl Acad Sci U S A. 2013;110:20242–7. doi: 10.1073/pnas.1320041110.</Citation><ArticleIdList><ArticleId IdType="doi">10.1073/pnas.1320041110</ArticleId><ArticleId IdType="pmc">PMC3864303</ArticleId><ArticleId IdType="pubmed">24277851</ArticleId></ArticleIdList></Reference></ReferenceList></PubmedData></PubmedArticle>